{"entity":"regeneron-pharmaceuticals","name":"Regeneron Pharmaceuticals","kind":null,"summary":"Regeneron Pharmaceuticals' timeline holds 514 claims from 1988 to 2026: 2 people, 504 money & deals, 8 other. 7 are undated. The latest took effect on September 30, 2026.","counts":{"total":514,"by_kind":{"people":2,"money":504,"products":0,"models":0,"other":8}},"events":[{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cik: 0000872589\", undated. Claim clm_0D4E584017A3, https://asof.is/claim/clm_0D4E584017A3, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_0D4E584017A3","accessed":"2026-11-09"},"kind":"other","predicate":"cik","value":"0000872589","status":"valid","assertable":true,"id":"clm_0D4E584017A3","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals fiscal year end: 12-31\", undated. Claim clm_2BC841F0E994, https://asof.is/claim/clm_2BC841F0E994, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_2BC841F0E994","accessed":"2026-11-09"},"kind":"other","predicate":"fiscal_year_end","value":"12-31","status":"valid","assertable":true,"id":"clm_2BC841F0E994","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals state of incorporation: NY\", undated. Claim clm_2EE7611EC44C, https://asof.is/claim/clm_2EE7611EC44C, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_2EE7611EC44C","accessed":"2026-11-09"},"kind":"other","predicate":"state_of_incorporation","value":"NY","status":"valid","assertable":true,"id":"clm_2EE7611EC44C","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals headquarters: Tarrytown\", undated. Claim clm_4EBDB058F389, https://asof.is/claim/clm_4EBDB058F389, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_4EBDB058F389","accessed":"2026-11-09"},"kind":"other","predicate":"headquarters","value":"Tarrytown","status":"valid","assertable":true,"id":"clm_4EBDB058F389","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals listed on: Nasdaq\", undated. Claim clm_60E05C2B8B5C, https://asof.is/claim/clm_60E05C2B8B5C, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_60E05C2B8B5C","accessed":"2026-11-09"},"kind":"other","predicate":"listed_on","value":"Nasdaq","status":"valid","assertable":true,"id":"clm_60E05C2B8B5C","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_BAC78AB8CD88, https://asof.is/claim/clm_BAC78AB8CD88, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_BAC78AB8CD88","accessed":"2026-11-09"},"kind":"other","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","status":"valid","assertable":true,"id":"clm_BAC78AB8CD88","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals ticker: REGN\", undated. Claim clm_CE8DC6176B9E, https://asof.is/claim/clm_CE8DC6176B9E, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_CE8DC6176B9E","accessed":"2026-11-09"},"kind":"other","predicate":"ticker","value":"REGN","status":"valid","assertable":true,"id":"clm_CE8DC6176B9E","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":"1988-01-01","until":null,"published":"2026-04-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals ceo: Leonard S. Schleifer\", as of 1988-01-01. Claim clm_31DC6D4DC56C, https://asof.is/claim/clm_31DC6D4DC56C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm.","url":"https://asof.is/claim/clm_31DC6D4DC56C","accessed":"2026-11-09"},"kind":"people","predicate":"ceo","value":"Leonard S. Schleifer","status":"valid","assertable":true,"id":"clm_31DC6D4DC56C","evidence":{"by":"page-read","on":"2026-11-08","quote":"Leonard S. Schleifer, M.D., Ph.D., 73, founded the Company in 1988 and has been a director and its President and Chief Executive Officer since its inception.","url":"https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm"}},{"date":"1995-07-26","until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals registrant name: REGENERON PHARMACEUTICALS, INC.\", as of 1995-07-26. Claim clm_0230630DE966, https://asof.is/claim/clm_0230630DE966, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_0230630DE966","accessed":"2026-11-09"},"kind":"other","predicate":"registrant_name","value":"REGENERON PHARMACEUTICALS, INC.","status":"valid","assertable":true,"id":"clm_0230630DE966","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":"2007-12-31","until":"2008-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 498,925,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_E2D362DD631E, https://asof.is/claim/clm_E2D362DD631E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_E2D362DD631E","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"498,925,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E2D362DD631E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-17"}},{"date":"2007-12-31","until":"2008-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 459,348,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_E47A2EAF4706, https://asof.is/claim/clm_E47A2EAF4706, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_E47A2EAF4706","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"459,348,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E47A2EAF4706","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2010, filed 2011-02-17"}},{"date":"2008-12-31","until":"2009-06-30","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 421,514,000 United States dollar\", as of 2008-12-31 (until 2009-06-30). Claim clm_27270E64C661, https://asof.is/claim/clm_27270E64C661, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_27270E64C661","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"421,514,000 United States dollar","status":"superseded","assertable":true,"id":"clm_27270E64C661","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2010, filed 2011-02-17"}},{"date":"2008-12-31","until":"2009-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: -86,249,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_3E8FF1B94F70, https://asof.is/claim/clm_3E8FF1B94F70, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_3E8FF1B94F70","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"-86,249,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3E8FF1B94F70","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2010, filed 2011-02-17"}},{"date":"2008-12-31","until":"2009-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: -79,129,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_7DFF0FB9DC16, https://asof.is/claim/clm_7DFF0FB9DC16, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_7DFF0FB9DC16","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"-79,129,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7DFF0FB9DC16","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2010, filed 2011-02-17"}},{"date":"2008-12-31","until":"2009-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 274,903,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_9548E82DE9F9, https://asof.is/claim/clm_9548E82DE9F9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_9548E82DE9F9","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"274,903,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9548E82DE9F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2010, filed 2011-02-17"}},{"date":"2008-12-31","until":"2009-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 238,457,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_BC2C8A20F65B, https://asof.is/claim/clm_BC2C8A20F65B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_BC2C8A20F65B","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"238,457,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BC2C8A20F65B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2010, filed 2011-02-17"}},{"date":"2008-12-31","until":"2009-06-30","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 247,796,000 United States dollar\", as of 2008-12-31 (until 2009-06-30). Claim clm_BC8073BF4473, https://asof.is/claim/clm_BC8073BF4473, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_BC8073BF4473","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"247,796,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BC8073BF4473","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-17"}},{"date":"2009-06-30","until":"2009-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 90,032,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_8F23955A5DC1, https://asof.is/claim/clm_8F23955A5DC1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_8F23955A5DC1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"90,032,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F23955A5DC1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2009-06-30","until":"2009-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 94,231,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_929B1DC18D5F, https://asof.is/claim/clm_929B1DC18D5F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_929B1DC18D5F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"94,231,000 United States dollar","status":"superseded","assertable":true,"id":"clm_929B1DC18D5F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2009-06-30","until":"2009-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: -16,266,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_B2E1F9844DD6, https://asof.is/claim/clm_B2E1F9844DD6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_B2E1F9844DD6","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"-16,266,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B2E1F9844DD6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2009-06-30","until":"2009-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 271,466,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_BA6D5CDEA514, https://asof.is/claim/clm_BA6D5CDEA514, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_BA6D5CDEA514","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"271,466,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BA6D5CDEA514","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2009-06-30","until":"2009-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 410,506,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_C2FCE96BEF20, https://asof.is/claim/clm_C2FCE96BEF20, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_C2FCE96BEF20","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"410,506,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C2FCE96BEF20","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2009-06-30","until":"2009-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: -14,938,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_FE7982325BDD, https://asof.is/claim/clm_FE7982325BDD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_FE7982325BDD","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"-14,938,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FE7982325BDD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2009-09-30","until":"2010-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 117,455,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_180A6BFB73AB, https://asof.is/claim/clm_180A6BFB73AB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_180A6BFB73AB","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"117,455,000 United States dollar","status":"superseded","assertable":true,"id":"clm_180A6BFB73AB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2009-09-30","until":"2010-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: -1,291,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_1C4BAC822C1D, https://asof.is/claim/clm_1C4BAC822C1D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_1C4BAC822C1D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"-1,291,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1C4BAC822C1D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2009-09-30","until":"2009-12-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 422,443,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_1E23E8E53794, https://asof.is/claim/clm_1E23E8E53794, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_1E23E8E53794","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"422,443,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1E23E8E53794","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2009-09-30","until":"2009-12-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 250,321,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_7918862037C1, https://asof.is/claim/clm_7918862037C1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_7918862037C1","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"250,321,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7918862037C1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2009-09-30","until":"2010-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: -1,015,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_AFED42FED572, https://asof.is/claim/clm_AFED42FED572, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_AFED42FED572","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"-1,015,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AFED42FED572","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2009-09-30","until":"2010-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 105,434,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_BF74EFFD510C, https://asof.is/claim/clm_BF74EFFD510C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_BF74EFFD510C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"105,434,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF74EFFD510C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2009-12-31","until":"2010-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: -67,830,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_4BD3F29C30C3, https://asof.is/claim/clm_4BD3F29C30C3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_4BD3F29C30C3","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"-67,830,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4BD3F29C30C3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2010, filed 2011-02-17"}},{"date":"2009-12-31","until":"2010-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 207,075,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_627E980C26AD, https://asof.is/claim/clm_627E980C26AD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_627E980C26AD","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"207,075,000 United States dollar","status":"superseded","assertable":true,"id":"clm_627E980C26AD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-17"}},{"date":"2009-12-31","until":"2010-06-30","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 741,202,000 United States dollar\", as of 2009-12-31 (until 2010-06-30). Claim clm_6561AF99BE78, https://asof.is/claim/clm_6561AF99BE78, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_6561AF99BE78","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"741,202,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6561AF99BE78","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2010, filed 2011-02-17"}},{"date":"2009-12-31","until":"2010-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 398,762,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_8BB3624F55A2, https://asof.is/claim/clm_8BB3624F55A2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_8BB3624F55A2","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"398,762,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8BB3624F55A2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2010, filed 2011-02-17"}},{"date":"2009-12-31","until":"2010-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 396,762,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_C14FC9DD9C3D, https://asof.is/claim/clm_C14FC9DD9C3D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_C14FC9DD9C3D","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"396,762,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C14FC9DD9C3D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2010, filed 2011-02-17"}},{"date":"2009-12-31","until":"2010-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: -74,103,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_C6F910B9B23D, https://asof.is/claim/clm_C6F910B9B23D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_C6F910B9B23D","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"-74,103,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C6F910B9B23D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2010, filed 2011-02-17"}},{"date":"2009-12-31","until":"2010-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 379,268,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_F4AAD27D2977, https://asof.is/claim/clm_F4AAD27D2977, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_F4AAD27D2977","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"379,268,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F4AAD27D2977","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2010, filed 2011-02-17"}},{"date":"2010-03-31","until":"2010-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 117,311,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_078E98AC1ADB, https://asof.is/claim/clm_078E98AC1ADB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_078E98AC1ADB","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"117,311,000 United States dollar","status":"superseded","assertable":true,"id":"clm_078E98AC1ADB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2010-03-31","until":"2010-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: -30,522,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_7AF7234E1826, https://asof.is/claim/clm_7AF7234E1826, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_7AF7234E1826","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"-30,522,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7AF7234E1826","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2010-03-31","until":"2010-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: -28,877,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_802C2C55FF06, https://asof.is/claim/clm_802C2C55FF06, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_802C2C55FF06","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"-28,877,000 United States dollar","status":"superseded","assertable":true,"id":"clm_802C2C55FF06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2010-03-31","until":"2010-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 117,471,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_B517328AE72E, https://asof.is/claim/clm_B517328AE72E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_B517328AE72E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"117,471,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B517328AE72E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2010-03-31","until":"2010-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 103,534,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_C140F465B911, https://asof.is/claim/clm_C140F465B911, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_C140F465B911","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"103,534,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C140F465B911","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2010-03-31","until":"2010-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 386,271,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_CBE9497E634B, https://asof.is/claim/clm_CBE9497E634B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_CBE9497E634B","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"386,271,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CBE9497E634B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: -23,724,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_4766DAD2B8E4, https://asof.is/claim/clm_4766DAD2B8E4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_4766DAD2B8E4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"-23,724,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4766DAD2B8E4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 124,526,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_50D037B8E10B, https://asof.is/claim/clm_50D037B8E10B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_50D037B8E10B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"124,526,000 United States dollar","status":"superseded","assertable":true,"id":"clm_50D037B8E10B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: -25,474,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_620FABA54C3D, https://asof.is/claim/clm_620FABA54C3D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_620FABA54C3D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"-25,474,000 United States dollar","status":"superseded","assertable":true,"id":"clm_620FABA54C3D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 115,886,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_627655F53872, https://asof.is/claim/clm_627655F53872, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_627655F53872","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"115,886,000 United States dollar","status":"superseded","assertable":true,"id":"clm_627655F53872","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 112,000,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_BBF34107EC0B, https://asof.is/claim/clm_BBF34107EC0B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_BBF34107EC0B","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"112,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BBF34107EC0B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 790,641,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_BD65B570A4E4, https://asof.is/claim/clm_BD65B570A4E4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_BD65B570A4E4","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"790,641,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BD65B570A4E4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 371,216,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_E4A47C6EE8A9, https://asof.is/claim/clm_E4A47C6EE8A9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_E4A47C6EE8A9","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"371,216,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E4A47C6EE8A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2010-07-15","until":"2010-10-15","published":"2010-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 79,931,305 shares\", as of 2010-07-15 (until 2010-10-15). Claim clm_34FD3B78CE3A, https://asof.is/claim/clm_34FD3B78CE3A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm.","url":"https://asof.is/claim/clm_34FD3B78CE3A","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"79,931,305 shares","status":"superseded","assertable":true,"id":"clm_34FD3B78CE3A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2010, filed 2010-07-28"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: -33,875,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_28ABCB90078C, https://asof.is/claim/clm_28ABCB90078C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_28ABCB90078C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"-33,875,000 United States dollar","status":"superseded","assertable":true,"id":"clm_28ABCB90078C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 942,433,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_48CC933138DD, https://asof.is/claim/clm_48CC933138DD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_48CC933138DD","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"942,433,000 United States dollar","status":"superseded","assertable":true,"id":"clm_48CC933138DD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 348,064,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_64A26E8ED78A, https://asof.is/claim/clm_64A26E8ED78A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_64A26E8ED78A","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"348,064,000 United States dollar","status":"superseded","assertable":true,"id":"clm_64A26E8ED78A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 325,286,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_B61AEABD9233, https://asof.is/claim/clm_B61AEABD9233, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_B61AEABD9233","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"325,286,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B61AEABD9233","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: -32,094,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_BA0DB10F3D70, https://asof.is/claim/clm_BA0DB10F3D70, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_BA0DB10F3D70","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"-32,094,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BA0DB10F3D70","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 122,043,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_C839FB986331, https://asof.is/claim/clm_C839FB986331, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_C839FB986331","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"122,043,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C839FB986331","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 105,979,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_E85633B203A9, https://asof.is/claim/clm_E85633B203A9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_E85633B203A9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"105,979,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E85633B203A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2010-10-15","until":"2011-02-11","published":"2010-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 80,111,128 shares\", as of 2010-10-15 (until 2011-02-11). Claim clm_8E21F9F74138, https://asof.is/claim/clm_8E21F9F74138, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm.","url":"https://asof.is/claim/clm_8E21F9F74138","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"80,111,128 shares","status":"superseded","assertable":true,"id":"clm_8E21F9F74138","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2010, filed 2010-10-28"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: -97,472,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_244D0F6FC089, https://asof.is/claim/clm_244D0F6FC089, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_244D0F6FC089","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"-97,472,000 United States dollar","status":"superseded","assertable":true,"id":"clm_244D0F6FC089","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2010, filed 2011-02-17"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 112,572,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_25FEBCAE80F4, https://asof.is/claim/clm_25FEBCAE80F4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_25FEBCAE80F4","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"112,572,000 United States dollar","status":"superseded","assertable":true,"id":"clm_25FEBCAE80F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-17"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 1,089,432,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_29EB7E3E7FF4, https://asof.is/claim/clm_29EB7E3E7FF4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_29EB7E3E7FF4","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"1,089,432,000 United States dollar","status":"superseded","assertable":true,"id":"clm_29EB7E3E7FF4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2010, filed 2011-02-17"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 527,815,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_5007EE5455F4, https://asof.is/claim/clm_5007EE5455F4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_5007EE5455F4","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"527,815,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5007EE5455F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2010, filed 2011-02-17"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: -104,468,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_9855FD3A29B1, https://asof.is/claim/clm_9855FD3A29B1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_9855FD3A29B1","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"-104,468,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9855FD3A29B1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2010, filed 2011-02-17"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 459,074,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_9A959E160676, https://asof.is/claim/clm_9A959E160676, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_9A959E160676","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"459,074,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9A959E160676","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2010, filed 2011-02-17"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 489,252,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_DBA4D7F8FE2B, https://asof.is/claim/clm_DBA4D7F8FE2B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_DBA4D7F8FE2B","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"489,252,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DBA4D7F8FE2B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2010, filed 2011-02-17"}},{"date":"2011-02-11","until":"2011-04-13","published":"2011-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 87,777,008 shares\", as of 2011-02-11 (until 2011-04-13). Claim clm_9F1578405220, https://asof.is/claim/clm_9F1578405220, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm.","url":"https://asof.is/claim/clm_9F1578405220","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"87,777,008 shares","status":"superseded","assertable":true,"id":"clm_9F1578405220","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2010, filed 2011-02-17"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 1,074,293,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_041DF9FBC553, https://asof.is/claim/clm_041DF9FBC553, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_041DF9FBC553","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"1,074,293,000 United States dollar","status":"superseded","assertable":true,"id":"clm_041DF9FBC553","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: -40,981,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_12E93F04613F, https://asof.is/claim/clm_12E93F04613F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_12E93F04613F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"-40,981,000 United States dollar","status":"superseded","assertable":true,"id":"clm_12E93F04613F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 129,392,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_371C6065B00F, https://asof.is/claim/clm_371C6065B00F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_371C6065B00F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"129,392,000 United States dollar","status":"superseded","assertable":true,"id":"clm_371C6065B00F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 112,204,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_6475C30104FE, https://asof.is/claim/clm_6475C30104FE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_6475C30104FE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"112,204,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6475C30104FE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 135,376,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_9135C6B074D1, https://asof.is/claim/clm_9135C6B074D1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_9135C6B074D1","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"135,376,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9135C6B074D1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 518,091,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_91765377ED79, https://asof.is/claim/clm_91765377ED79, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_91765377ED79","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"518,091,000 United States dollar","status":"superseded","assertable":true,"id":"clm_91765377ED79","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: -43,447,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_EBB8DD46F73B, https://asof.is/claim/clm_EBB8DD46F73B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_EBB8DD46F73B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"-43,447,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EBB8DD46F73B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2011-04-13","until":"2011-07-15","published":"2011-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 88,739,294 shares\", as of 2011-04-13 (until 2011-07-15). Claim clm_4A8E4990BE56, https://asof.is/claim/clm_4A8E4990BE56, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm.","url":"https://asof.is/claim/clm_4A8E4990BE56","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"88,739,294 shares","status":"superseded","assertable":true,"id":"clm_4A8E4990BE56","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2011, filed 2011-05-03"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 143,149,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_0F6159727C59, https://asof.is/claim/clm_0F6159727C59, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001639/0001206774-11-001639-index.htm.","url":"https://asof.is/claim/clm_0F6159727C59","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"143,149,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0F6159727C59","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2011, filed 2011-07-28"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 1,046,864,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_34A57EEA9DE6, https://asof.is/claim/clm_34A57EEA9DE6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001639/0001206774-11-001639-index.htm.","url":"https://asof.is/claim/clm_34A57EEA9DE6","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"1,046,864,000 United States dollar","status":"superseded","assertable":true,"id":"clm_34A57EEA9DE6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2011, filed 2011-07-28"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 478,034,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_510855B8D0BD, https://asof.is/claim/clm_510855B8D0BD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001639/0001206774-11-001639-index.htm.","url":"https://asof.is/claim/clm_510855B8D0BD","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"478,034,000 United States dollar","status":"superseded","assertable":true,"id":"clm_510855B8D0BD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2011, filed 2011-07-28"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: -60,319,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_5DD062633A03, https://asof.is/claim/clm_5DD062633A03, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001639/0001206774-11-001639-index.htm.","url":"https://asof.is/claim/clm_5DD062633A03","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"-60,319,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5DD062633A03","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2011, filed 2011-07-28"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 254,312,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_6BA60CDC0B9D, https://asof.is/claim/clm_6BA60CDC0B9D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001639/0001206774-11-001639-index.htm.","url":"https://asof.is/claim/clm_6BA60CDC0B9D","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"254,312,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6BA60CDC0B9D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2011, filed 2011-07-28"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 107,810,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_A35410AC229A, https://asof.is/claim/clm_A35410AC229A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001639/0001206774-11-001639-index.htm.","url":"https://asof.is/claim/clm_A35410AC229A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"107,810,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A35410AC229A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2011, filed 2011-07-28"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: -62,505,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_BEE2EE1A4F91, https://asof.is/claim/clm_BEE2EE1A4F91, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001639/0001206774-11-001639-index.htm.","url":"https://asof.is/claim/clm_BEE2EE1A4F91","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"-62,505,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BEE2EE1A4F91","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2011, filed 2011-07-28"}},{"date":"2011-07-15","until":"2011-10-19","published":"2011-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 89,499,900 shares\", as of 2011-07-15 (until 2011-10-19). Claim clm_EAEA070624D5, https://asof.is/claim/clm_EAEA070624D5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411001639/0001206774-11-001639-index.htm.","url":"https://asof.is/claim/clm_EAEA070624D5","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"89,499,900 shares","status":"superseded","assertable":true,"id":"clm_EAEA070624D5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2011, filed 2011-07-28"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 428,253,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_1330872EE468, https://asof.is/claim/clm_1330872EE468, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411002300/0001206774-11-002300-index.htm.","url":"https://asof.is/claim/clm_1330872EE468","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"428,253,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1330872EE468","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2011, filed 2011-10-27"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 983,031,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_377708CC6732, https://asof.is/claim/clm_377708CC6732, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411002300/0001206774-11-002300-index.htm.","url":"https://asof.is/claim/clm_377708CC6732","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"983,031,000 United States dollar","status":"superseded","assertable":true,"id":"clm_377708CC6732","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2011, filed 2011-10-27"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: -58,457,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_3B9F0AEC9660, https://asof.is/claim/clm_3B9F0AEC9660, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411002300/0001206774-11-002300-index.htm.","url":"https://asof.is/claim/clm_3B9F0AEC9660","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"-58,457,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3B9F0AEC9660","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2011, filed 2011-10-27"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 206,395,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_8F646FBC58B0, https://asof.is/claim/clm_8F646FBC58B0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411002300/0001206774-11-002300-index.htm.","url":"https://asof.is/claim/clm_8F646FBC58B0","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"206,395,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F646FBC58B0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2011, filed 2011-10-27"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 127,924,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_D248A8950FA4, https://asof.is/claim/clm_D248A8950FA4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411002300/0001206774-11-002300-index.htm.","url":"https://asof.is/claim/clm_D248A8950FA4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"127,924,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D248A8950FA4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2011, filed 2011-10-27"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 102,833,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_EC0E16DDB2D8, https://asof.is/claim/clm_EC0E16DDB2D8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411002300/0001206774-11-002300-index.htm.","url":"https://asof.is/claim/clm_EC0E16DDB2D8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"102,833,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EC0E16DDB2D8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2011, filed 2011-10-27"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: -62,365,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_FBBAE356E784, https://asof.is/claim/clm_FBBAE356E784, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411002300/0001206774-11-002300-index.htm.","url":"https://asof.is/claim/clm_FBBAE356E784","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"-62,365,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FBBAE356E784","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2011, filed 2011-10-27"}},{"date":"2011-10-19","until":"2012-02-10","published":"2011-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 90,466,178 shares\", as of 2011-10-19 (until 2012-02-10). Claim clm_1AE57BD8CE95, https://asof.is/claim/clm_1AE57BD8CE95, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677411002300/0001206774-11-002300-index.htm.","url":"https://asof.is/claim/clm_1AE57BD8CE95","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"90,466,178 shares","status":"superseded","assertable":true,"id":"clm_1AE57BD8CE95","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2011, filed 2011-10-27"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 445,824,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_32D9C9A4307F, https://asof.is/claim/clm_32D9C9A4307F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412000709/0001206774-12-000709-index.htm.","url":"https://asof.is/claim/clm_32D9C9A4307F","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"445,824,000 United States dollar","status":"superseded","assertable":true,"id":"clm_32D9C9A4307F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2011, filed 2012-02-21"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 1,323,583,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_545A6A3B5E05, https://asof.is/claim/clm_545A6A3B5E05, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412000709/0001206774-12-000709-index.htm.","url":"https://asof.is/claim/clm_545A6A3B5E05","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"1,323,583,000 United States dollar","status":"superseded","assertable":true,"id":"clm_545A6A3B5E05","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2011, filed 2012-02-21"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 485,732,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_589084C462D0, https://asof.is/claim/clm_589084C462D0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412000709/0001206774-12-000709-index.htm.","url":"https://asof.is/claim/clm_589084C462D0","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"485,732,000 United States dollar","status":"superseded","assertable":true,"id":"clm_589084C462D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2011, filed 2012-02-21"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 529,506,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_9C8A4A104B4F, https://asof.is/claim/clm_9C8A4A104B4F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412000709/0001206774-12-000709-index.htm.","url":"https://asof.is/claim/clm_9C8A4A104B4F","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"529,506,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9C8A4A104B4F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2011, filed 2012-02-21"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 483,610,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_C5F7ECAA4C25, https://asof.is/claim/clm_C5F7ECAA4C25, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412000709/0001206774-12-000709-index.htm.","url":"https://asof.is/claim/clm_C5F7ECAA4C25","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"483,610,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C5F7ECAA4C25","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2011, filed 2012-02-21"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: -205,159,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_E89A362E23D2, https://asof.is/claim/clm_E89A362E23D2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412000709/0001206774-12-000709-index.htm.","url":"https://asof.is/claim/clm_E89A362E23D2","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"-205,159,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E89A362E23D2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2011, filed 2012-02-21"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: -221,760,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_F3AAA9683DBE, https://asof.is/claim/clm_F3AAA9683DBE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412000709/0001206774-12-000709-index.htm.","url":"https://asof.is/claim/clm_F3AAA9683DBE","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"-221,760,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F3AAA9683DBE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2011, filed 2012-02-21"}},{"date":"2012-02-10","until":"2012-04-11","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 91,779,465 shares\", as of 2012-02-10 (until 2012-04-11). Claim clm_CC510D3CC49D, https://asof.is/claim/clm_CC510D3CC49D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412000709/0001206774-12-000709-index.htm.","url":"https://asof.is/claim/clm_CC510D3CC49D","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"91,779,465 shares","status":"superseded","assertable":true,"id":"clm_CC510D3CC49D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2011, filed 2012-02-21"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 394,585,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_887DBFDB9082, https://asof.is/claim/clm_887DBFDB9082, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm.","url":"https://asof.is/claim/clm_887DBFDB9082","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"394,585,000 United States dollar","status":"superseded","assertable":true,"id":"clm_887DBFDB9082","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2012, filed 2012-04-26"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 1,350,159,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_ADE56CD2A2B3, https://asof.is/claim/clm_ADE56CD2A2B3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm.","url":"https://asof.is/claim/clm_ADE56CD2A2B3","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"1,350,159,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ADE56CD2A2B3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2012, filed 2012-04-26"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 231,789,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_C5D81A308356, https://asof.is/claim/clm_C5D81A308356, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm.","url":"https://asof.is/claim/clm_C5D81A308356","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"231,789,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C5D81A308356","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2012, filed 2012-04-26"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 22,201,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_C93221C62CF4, https://asof.is/claim/clm_C93221C62CF4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm.","url":"https://asof.is/claim/clm_C93221C62CF4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"22,201,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C93221C62CF4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2012, filed 2012-04-26"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 504,024,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_DBC9DBB0188D, https://asof.is/claim/clm_DBC9DBB0188D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm.","url":"https://asof.is/claim/clm_DBC9DBB0188D","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"504,024,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DBC9DBB0188D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2012, filed 2012-04-26"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 11,651,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_DE7CE27F0752, https://asof.is/claim/clm_DE7CE27F0752, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm.","url":"https://asof.is/claim/clm_DE7CE27F0752","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"11,651,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DE7CE27F0752","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2012, filed 2012-04-26"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 138,862,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_F56438C2065F, https://asof.is/claim/clm_F56438C2065F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm.","url":"https://asof.is/claim/clm_F56438C2065F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"138,862,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F56438C2065F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2012, filed 2012-04-26"}},{"date":"2012-04-11","until":"2012-07-13","published":"2012-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 93,032,889 shares\", as of 2012-04-11 (until 2012-07-13). Claim clm_577DFD723982, https://asof.is/claim/clm_577DFD723982, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm.","url":"https://asof.is/claim/clm_577DFD723982","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"93,032,889 shares","status":"superseded","assertable":true,"id":"clm_577DFD723982","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2012, filed 2012-04-26"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 147,373,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_1557BB809F3B, https://asof.is/claim/clm_1557BB809F3B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm.","url":"https://asof.is/claim/clm_1557BB809F3B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"147,373,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1557BB809F3B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2012, filed 2012-07-25"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 171,943,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_511459233BCE, https://asof.is/claim/clm_511459233BCE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm.","url":"https://asof.is/claim/clm_511459233BCE","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"171,943,000 United States dollar","status":"superseded","assertable":true,"id":"clm_511459233BCE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2012, filed 2012-07-25"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 594,657,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_9E8EECD34DB3, https://asof.is/claim/clm_9E8EECD34DB3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm.","url":"https://asof.is/claim/clm_9E8EECD34DB3","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"594,657,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9E8EECD34DB3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2012, filed 2012-07-25"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 1,457,500,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_A3017E7DE44C, https://asof.is/claim/clm_A3017E7DE44C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm.","url":"https://asof.is/claim/clm_A3017E7DE44C","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"1,457,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A3017E7DE44C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2012, filed 2012-07-25"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 87,478,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_C01BAE2ED355, https://asof.is/claim/clm_C01BAE2ED355, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm.","url":"https://asof.is/claim/clm_C01BAE2ED355","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"87,478,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C01BAE2ED355","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2012, filed 2012-07-25"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 76,743,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_C602747CFC82, https://asof.is/claim/clm_C602747CFC82, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm.","url":"https://asof.is/claim/clm_C602747CFC82","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"76,743,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C602747CFC82","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2012, filed 2012-07-25"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 304,399,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_F838E1612E57, https://asof.is/claim/clm_F838E1612E57, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm.","url":"https://asof.is/claim/clm_F838E1612E57","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"304,399,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F838E1612E57","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2012, filed 2012-07-25"}},{"date":"2012-07-13","until":null,"published":"2012-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 93,955,110 shares\", as of 2012-07-13. Claim clm_24C3500A1DEF, https://asof.is/claim/clm_24C3500A1DEF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm.","url":"https://asof.is/claim/clm_24C3500A1DEF","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"93,955,110 shares","status":"valid","assertable":true,"id":"clm_24C3500A1DEF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2012, filed 2012-07-25"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-10-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 806,024,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_1DFB726EC635, https://asof.is/claim/clm_1DFB726EC635, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217612000004/0001532176-12-000004-index.htm.","url":"https://asof.is/claim/clm_1DFB726EC635","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"806,024,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1DFB726EC635","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2012, filed 2012-10-24"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-10-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 118,998,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_6A776163AAFA, https://asof.is/claim/clm_6A776163AAFA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217612000004/0001532176-12-000004-index.htm.","url":"https://asof.is/claim/clm_6A776163AAFA","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"118,998,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6A776163AAFA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2012, filed 2012-10-24"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-10-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 427,687,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_82AF3B3F2E9E, https://asof.is/claim/clm_82AF3B3F2E9E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217612000004/0001532176-12-000004-index.htm.","url":"https://asof.is/claim/clm_82AF3B3F2E9E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"427,687,000 United States dollar","status":"superseded","assertable":true,"id":"clm_82AF3B3F2E9E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2012, filed 2012-10-24"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-10-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 1,660,615,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_8DFDB982480A, https://asof.is/claim/clm_8DFDB982480A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217612000004/0001532176-12-000004-index.htm.","url":"https://asof.is/claim/clm_8DFDB982480A","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"1,660,615,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8DFDB982480A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2012, filed 2012-10-24"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-10-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 202,364,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_9ECACDE79861, https://asof.is/claim/clm_9ECACDE79861, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217612000004/0001532176-12-000004-index.htm.","url":"https://asof.is/claim/clm_9ECACDE79861","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"202,364,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9ECACDE79861","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2012, filed 2012-10-24"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-10-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 191,468,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_B873B34DF388, https://asof.is/claim/clm_B873B34DF388, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217612000004/0001532176-12-000004-index.htm.","url":"https://asof.is/claim/clm_B873B34DF388","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"191,468,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B873B34DF388","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2012, filed 2012-10-24"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-10-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 158,295,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_E00C8F83DE93, https://asof.is/claim/clm_E00C8F83DE93, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217612000004/0001532176-12-000004-index.htm.","url":"https://asof.is/claim/clm_E00C8F83DE93","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"158,295,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E00C8F83DE93","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2012, filed 2012-10-24"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 1,378,477,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_0B45DD87AE68, https://asof.is/claim/clm_0B45DD87AE68, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000004/0001532176-13-000004-index.htm.","url":"https://asof.is/claim/clm_0B45DD87AE68","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"1,378,477,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0B45DD87AE68","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2012, filed 2013-02-15"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 625,554,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_1BAC3F81B511, https://asof.is/claim/clm_1BAC3F81B511, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000004/0001532176-13-000004-index.htm.","url":"https://asof.is/claim/clm_1BAC3F81B511","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"625,554,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1BAC3F81B511","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2012, filed 2013-02-15"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 230,276,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_1E166CBF8C7E, https://asof.is/claim/clm_1E166CBF8C7E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000004/0001532176-13-000004-index.htm.","url":"https://asof.is/claim/clm_1E166CBF8C7E","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"230,276,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1E166CBF8C7E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2012, filed 2013-02-15"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 750,269,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_2F265702ECB5, https://asof.is/claim/clm_2F265702ECB5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000004/0001532176-13-000004-index.htm.","url":"https://asof.is/claim/clm_2F265702ECB5","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"750,269,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2F265702ECB5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2012, filed 2013-02-15"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 457,713,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_38E3B92F967E, https://asof.is/claim/clm_38E3B92F967E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000004/0001532176-13-000004-index.htm.","url":"https://asof.is/claim/clm_38E3B92F967E","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"457,713,000 United States dollar","status":"superseded","assertable":true,"id":"clm_38E3B92F967E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2012, filed 2013-02-15"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 2,080,490,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_A372EDBC91D9, https://asof.is/claim/clm_A372EDBC91D9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000004/0001532176-13-000004-index.htm.","url":"https://asof.is/claim/clm_A372EDBC91D9","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"2,080,490,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A372EDBC91D9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2012, filed 2013-02-15"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 1,245,385,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_B3960C0B2099, https://asof.is/claim/clm_B3960C0B2099, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000004/0001532176-13-000004-index.htm.","url":"https://asof.is/claim/clm_B3960C0B2099","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"1,245,385,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B3960C0B2099","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2012, filed 2013-02-15"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 180,299,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_0523CCD853F5, https://asof.is/claim/clm_0523CCD853F5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000008/0001532176-13-000008-index.htm.","url":"https://asof.is/claim/clm_0523CCD853F5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"180,299,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0523CCD853F5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 153,050,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_2573AC111BC6, https://asof.is/claim/clm_2573AC111BC6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000008/0001532176-13-000008-index.htm.","url":"https://asof.is/claim/clm_2573AC111BC6","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"153,050,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2573AC111BC6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 2,275,998,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_27AF6C1F02F9, https://asof.is/claim/clm_27AF6C1F02F9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000008/0001532176-13-000008-index.htm.","url":"https://asof.is/claim/clm_27AF6C1F02F9","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"2,275,998,000 United States dollar","status":"superseded","assertable":true,"id":"clm_27AF6C1F02F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 439,664,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_3E5F56BC8504, https://asof.is/claim/clm_3E5F56BC8504, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000008/0001532176-13-000008-index.htm.","url":"https://asof.is/claim/clm_3E5F56BC8504","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"439,664,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3E5F56BC8504","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 180,362,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_5F5113D9E628, https://asof.is/claim/clm_5F5113D9E628, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000008/0001532176-13-000008-index.htm.","url":"https://asof.is/claim/clm_5F5113D9E628","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"180,362,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5F5113D9E628","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 98,874,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_62038DF4A8A1, https://asof.is/claim/clm_62038DF4A8A1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000008/0001532176-13-000008-index.htm.","url":"https://asof.is/claim/clm_62038DF4A8A1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"98,874,000 United States dollar","status":"superseded","assertable":true,"id":"clm_62038DF4A8A1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 1,406,348,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_E05AB5ED8875, https://asof.is/claim/clm_E05AB5ED8875, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000008/0001532176-13-000008-index.htm.","url":"https://asof.is/claim/clm_E05AB5ED8875","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"1,406,348,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E05AB5ED8875","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 457,642,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_176F45465AD1, https://asof.is/claim/clm_176F45465AD1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000022/0001532176-13-000022-index.htm.","url":"https://asof.is/claim/clm_176F45465AD1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"457,642,000 United States dollar","status":"superseded","assertable":true,"id":"clm_176F45465AD1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 87,376,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_501F214D494B, https://asof.is/claim/clm_501F214D494B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000022/0001532176-13-000022-index.htm.","url":"https://asof.is/claim/clm_501F214D494B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"87,376,000 United States dollar","status":"superseded","assertable":true,"id":"clm_501F214D494B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 1,493,337,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_7E8E7F35A702, https://asof.is/claim/clm_7E8E7F35A702, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000022/0001532176-13-000022-index.htm.","url":"https://asof.is/claim/clm_7E8E7F35A702","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"1,493,337,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7E8E7F35A702","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 381,675,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_A67A80877FAD, https://asof.is/claim/clm_A67A80877FAD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000022/0001532176-13-000022-index.htm.","url":"https://asof.is/claim/clm_A67A80877FAD","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"381,675,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A67A80877FAD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 187,463,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_B00FA7DE5A26, https://asof.is/claim/clm_B00FA7DE5A26, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000022/0001532176-13-000022-index.htm.","url":"https://asof.is/claim/clm_B00FA7DE5A26","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"187,463,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B00FA7DE5A26","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 2,378,259,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_E6470153188B, https://asof.is/claim/clm_E6470153188B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000022/0001532176-13-000022-index.htm.","url":"https://asof.is/claim/clm_E6470153188B","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"2,378,259,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E6470153188B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 158,103,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_ED36DCD5E0B9, https://asof.is/claim/clm_ED36DCD5E0B9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000022/0001532176-13-000022-index.htm.","url":"https://asof.is/claim/clm_ED36DCD5E0B9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"158,103,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ED36DCD5E0B9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 224,045,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_33823C33ED82, https://asof.is/claim/clm_33823C33ED82, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000030/0001532176-13-000030-index.htm.","url":"https://asof.is/claim/clm_33823C33ED82","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"224,045,000 United States dollar","status":"superseded","assertable":true,"id":"clm_33823C33ED82","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2013, filed 2013-11-05"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 236,802,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_57F54C76F7C4, https://asof.is/claim/clm_57F54C76F7C4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000030/0001532176-13-000030-index.htm.","url":"https://asof.is/claim/clm_57F54C76F7C4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"236,802,000 United States dollar","status":"superseded","assertable":true,"id":"clm_57F54C76F7C4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2013, filed 2013-11-05"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 141,306,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_6400162ACAD1, https://asof.is/claim/clm_6400162ACAD1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000030/0001532176-13-000030-index.htm.","url":"https://asof.is/claim/clm_6400162ACAD1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"141,306,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6400162ACAD1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2013, filed 2013-11-05"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 2,640,415,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_81FEAF8A1B42, https://asof.is/claim/clm_81FEAF8A1B42, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000030/0001532176-13-000030-index.htm.","url":"https://asof.is/claim/clm_81FEAF8A1B42","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"2,640,415,000 United States dollar","status":"superseded","assertable":true,"id":"clm_81FEAF8A1B42","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2013, filed 2013-11-05"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 263,211,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_ADF4E3F0D091, https://asof.is/claim/clm_ADF4E3F0D091, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000030/0001532176-13-000030-index.htm.","url":"https://asof.is/claim/clm_ADF4E3F0D091","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"263,211,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ADF4E3F0D091","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2013, filed 2013-11-05"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 1,690,171,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_CF49D665F1F6, https://asof.is/claim/clm_CF49D665F1F6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000030/0001532176-13-000030-index.htm.","url":"https://asof.is/claim/clm_CF49D665F1F6","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"1,690,171,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CF49D665F1F6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2013, filed 2013-11-05"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 597,027,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_FFE707425BE2, https://asof.is/claim/clm_FFE707425BE2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217613000030/0001532176-13-000030-index.htm.","url":"https://asof.is/claim/clm_FFE707425BE2","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"597,027,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FFE707425BE2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2013, filed 2013-11-05"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 535,608,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_61B0FD9BE595, https://asof.is/claim/clm_61B0FD9BE595, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000008/0001532176-14-000008-index.htm.","url":"https://asof.is/claim/clm_61B0FD9BE595","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"535,608,000 United States dollar","status":"superseded","assertable":true,"id":"clm_61B0FD9BE595","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-13"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 760,028,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_8A99CD2AC1DF, https://asof.is/claim/clm_8A99CD2AC1DF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000008/0001532176-14-000008-index.htm.","url":"https://asof.is/claim/clm_8A99CD2AC1DF","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"760,028,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A99CD2AC1DF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2013, filed 2014-02-13"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 424,362,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_945579B45ED0, https://asof.is/claim/clm_945579B45ED0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000008/0001532176-14-000008-index.htm.","url":"https://asof.is/claim/clm_945579B45ED0","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"424,362,000 United States dollar","status":"superseded","assertable":true,"id":"clm_945579B45ED0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2013, filed 2014-02-13"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 2,104,745,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_9AAE36CED876, https://asof.is/claim/clm_9AAE36CED876, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000008/0001532176-14-000008-index.htm.","url":"https://asof.is/claim/clm_9AAE36CED876","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"2,104,745,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9AAE36CED876","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2013, filed 2014-02-13"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 2,951,013,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_9BF91030901D, https://asof.is/claim/clm_9BF91030901D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000008/0001532176-14-000008-index.htm.","url":"https://asof.is/claim/clm_9BF91030901D","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"2,951,013,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9BF91030901D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2013, filed 2014-02-13"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 859,947,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_D1E0932A289A, https://asof.is/claim/clm_D1E0932A289A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000008/0001532176-14-000008-index.htm.","url":"https://asof.is/claim/clm_D1E0932A289A","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"859,947,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D1E0932A289A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2013, filed 2014-02-13"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 1,952,076,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_D6EC6F37876A, https://asof.is/claim/clm_D6EC6F37876A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000008/0001532176-14-000008-index.htm.","url":"https://asof.is/claim/clm_D6EC6F37876A","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"1,952,076,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D6EC6F37876A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-13"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 65,443,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_241DC1271E83, https://asof.is/claim/clm_241DC1271E83, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000022/0001532176-14-000022-index.htm.","url":"https://asof.is/claim/clm_241DC1271E83","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"65,443,000 United States dollar","status":"superseded","assertable":true,"id":"clm_241DC1271E83","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 287,379,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_298FEDBEF107, https://asof.is/claim/clm_298FEDBEF107, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000022/0001532176-14-000022-index.htm.","url":"https://asof.is/claim/clm_298FEDBEF107","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"287,379,000 United States dollar","status":"superseded","assertable":true,"id":"clm_298FEDBEF107","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 2,211,248,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_60A1853443C7, https://asof.is/claim/clm_60A1853443C7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000022/0001532176-14-000022-index.htm.","url":"https://asof.is/claim/clm_60A1853443C7","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"2,211,248,000 United States dollar","status":"superseded","assertable":true,"id":"clm_60A1853443C7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 625,740,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_6885E2367C01, https://asof.is/claim/clm_6885E2367C01, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000022/0001532176-14-000022-index.htm.","url":"https://asof.is/claim/clm_6885E2367C01","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"625,740,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6885E2367C01","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 461,858,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_6964C7D213F4, https://asof.is/claim/clm_6964C7D213F4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000022/0001532176-14-000022-index.htm.","url":"https://asof.is/claim/clm_6964C7D213F4","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"461,858,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6964C7D213F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 185,939,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_7C0F51D70380, https://asof.is/claim/clm_7C0F51D70380, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000022/0001532176-14-000022-index.htm.","url":"https://asof.is/claim/clm_7C0F51D70380","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"185,939,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7C0F51D70380","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 3,260,396,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_9B09C4FBCC86, https://asof.is/claim/clm_9B09C4FBCC86, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000022/0001532176-14-000022-index.htm.","url":"https://asof.is/claim/clm_9B09C4FBCC86","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"3,260,396,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9B09C4FBCC86","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 294,501,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_3B3C62D2F90C, https://asof.is/claim/clm_3B3C62D2F90C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000035/0001532176-14-000035-index.htm.","url":"https://asof.is/claim/clm_3B3C62D2F90C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"294,501,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3B3C62D2F90C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 665,700,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_3B9F3E529762, https://asof.is/claim/clm_3B9F3E529762, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000035/0001532176-14-000035-index.htm.","url":"https://asof.is/claim/clm_3B9F3E529762","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"665,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3B9F3E529762","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 2,368,842,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_509A448302A2, https://asof.is/claim/clm_509A448302A2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000035/0001532176-14-000035-index.htm.","url":"https://asof.is/claim/clm_509A448302A2","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"2,368,842,000 United States dollar","status":"superseded","assertable":true,"id":"clm_509A448302A2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 3,456,078,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_71FBC7380A33, https://asof.is/claim/clm_71FBC7380A33, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000035/0001532176-14-000035-index.htm.","url":"https://asof.is/claim/clm_71FBC7380A33","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"3,456,078,000 United States dollar","status":"superseded","assertable":true,"id":"clm_71FBC7380A33","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 600,135,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_878C5CCBECBD, https://asof.is/claim/clm_878C5CCBECBD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000035/0001532176-14-000035-index.htm.","url":"https://asof.is/claim/clm_878C5CCBECBD","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"600,135,000 United States dollar","status":"superseded","assertable":true,"id":"clm_878C5CCBECBD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 92,735,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_D170703CFE06, https://asof.is/claim/clm_D170703CFE06, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000035/0001532176-14-000035-index.htm.","url":"https://asof.is/claim/clm_D170703CFE06","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"92,735,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D170703CFE06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 222,406,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_E091B4B6A620, https://asof.is/claim/clm_E091B4B6A620, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000035/0001532176-14-000035-index.htm.","url":"https://asof.is/claim/clm_E091B4B6A620","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"222,406,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E091B4B6A620","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 337,728,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_0EAC890E9792, https://asof.is/claim/clm_0EAC890E9792, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000046/0001532176-14-000046-index.htm.","url":"https://asof.is/claim/clm_0EAC890E9792","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"337,728,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0EAC890E9792","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2014, filed 2014-11-04"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 646,554,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_579D4C297D5C, https://asof.is/claim/clm_579D4C297D5C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000046/0001532176-14-000046-index.htm.","url":"https://asof.is/claim/clm_579D4C297D5C","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"646,554,000 United States dollar","status":"superseded","assertable":true,"id":"clm_579D4C297D5C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2014, filed 2014-11-04"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 2,551,788,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_5820D8A235B7, https://asof.is/claim/clm_5820D8A235B7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000046/0001532176-14-000046-index.htm.","url":"https://asof.is/claim/clm_5820D8A235B7","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"2,551,788,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5820D8A235B7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2014, filed 2014-11-04"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 182,719,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_80E41A8C086F, https://asof.is/claim/clm_80E41A8C086F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000046/0001532176-14-000046-index.htm.","url":"https://asof.is/claim/clm_80E41A8C086F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"182,719,000 United States dollar","status":"superseded","assertable":true,"id":"clm_80E41A8C086F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-04"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 79,720,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_96E0C48FCE1B, https://asof.is/claim/clm_96E0C48FCE1B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000046/0001532176-14-000046-index.htm.","url":"https://asof.is/claim/clm_96E0C48FCE1B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"79,720,000 United States dollar","status":"superseded","assertable":true,"id":"clm_96E0C48FCE1B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-04"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 725,788,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_D15D4A6E6B04, https://asof.is/claim/clm_D15D4A6E6B04, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000046/0001532176-14-000046-index.htm.","url":"https://asof.is/claim/clm_D15D4A6E6B04","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"725,788,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D15D4A6E6B04","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2014, filed 2014-11-04"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 3,739,419,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_E4D93A1F2B7B, https://asof.is/claim/clm_E4D93A1F2B7B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217614000046/0001532176-14-000046-index.htm.","url":"https://asof.is/claim/clm_E4D93A1F2B7B","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"3,739,419,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E4D93A1F2B7B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2014, filed 2014-11-04"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 648,719,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_6622B66FDA71, https://asof.is/claim/clm_6622B66FDA71, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000008/0001532176-15-000008-index.htm.","url":"https://asof.is/claim/clm_6622B66FDA71","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"648,719,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6622B66FDA71","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2014, filed 2015-02-12"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 2,819,557,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_81193541BA7F, https://asof.is/claim/clm_81193541BA7F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000008/0001532176-15-000008-index.htm.","url":"https://asof.is/claim/clm_81193541BA7F","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"2,819,557,000 United States dollar","status":"superseded","assertable":true,"id":"clm_81193541BA7F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2014, filed 2015-02-12"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 3,871,827,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_A1D3771334E7, https://asof.is/claim/clm_A1D3771334E7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000008/0001532176-15-000008-index.htm.","url":"https://asof.is/claim/clm_A1D3771334E7","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"3,871,827,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A1D3771334E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2014, filed 2015-02-12"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 2,542,325,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_B9965B5284FE, https://asof.is/claim/clm_B9965B5284FE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000008/0001532176-15-000008-index.htm.","url":"https://asof.is/claim/clm_B9965B5284FE","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"2,542,325,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B9965B5284FE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2014, filed 2015-02-12"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 838,431,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_BFC64F70A0E6, https://asof.is/claim/clm_BFC64F70A0E6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000008/0001532176-15-000008-index.htm.","url":"https://asof.is/claim/clm_BFC64F70A0E6","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"838,431,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BFC64F70A0E6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2014, filed 2015-02-12"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 348,074,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_D3F5BB8C7757, https://asof.is/claim/clm_D3F5BB8C7757, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000008/0001532176-15-000008-index.htm.","url":"https://asof.is/claim/clm_D3F5BB8C7757","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"348,074,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D3F5BB8C7757","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2014, filed 2015-02-12"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 1,271,353,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_EFF482F34611, https://asof.is/claim/clm_EFF482F34611, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000008/0001532176-15-000008-index.htm.","url":"https://asof.is/claim/clm_EFF482F34611","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"1,271,353,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EFF482F34611","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2014, filed 2015-02-12"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 283,553,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_0339E4418D85, https://asof.is/claim/clm_0339E4418D85, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000020/0001532176-15-000020-index.htm.","url":"https://asof.is/claim/clm_0339E4418D85","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"283,553,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0339E4418D85","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 507,907,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_1139EC91486A, https://asof.is/claim/clm_1139EC91486A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000020/0001532176-15-000020-index.htm.","url":"https://asof.is/claim/clm_1139EC91486A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"507,907,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1139EC91486A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 2,971,430,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_1AD620E8D1BF, https://asof.is/claim/clm_1AD620E8D1BF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000020/0001532176-15-000020-index.htm.","url":"https://asof.is/claim/clm_1AD620E8D1BF","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"2,971,430,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1AD620E8D1BF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 869,612,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_34333BB2CA3F, https://asof.is/claim/clm_34333BB2CA3F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000020/0001532176-15-000020-index.htm.","url":"https://asof.is/claim/clm_34333BB2CA3F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"869,612,000 United States dollar","status":"superseded","assertable":true,"id":"clm_34333BB2CA3F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 76,021,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_372DCD80253C, https://asof.is/claim/clm_372DCD80253C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000020/0001532176-15-000020-index.htm.","url":"https://asof.is/claim/clm_372DCD80253C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"76,021,000 United States dollar","status":"superseded","assertable":true,"id":"clm_372DCD80253C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 343,113,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_8ACDB2D459CA, https://asof.is/claim/clm_8ACDB2D459CA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000020/0001532176-15-000020-index.htm.","url":"https://asof.is/claim/clm_8ACDB2D459CA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"343,113,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8ACDB2D459CA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 4,198,573,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_B102B1165213, https://asof.is/claim/clm_B102B1165213, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000020/0001532176-15-000020-index.htm.","url":"https://asof.is/claim/clm_B102B1165213","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"4,198,573,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B102B1165213","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 998,617,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_50CADC50AD04, https://asof.is/claim/clm_50CADC50AD04, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000029/0001532176-15-000029-index.htm.","url":"https://asof.is/claim/clm_50CADC50AD04","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"998,617,000 United States dollar","status":"superseded","assertable":true,"id":"clm_50CADC50AD04","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 194,643,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_596AA50FD9A5, https://asof.is/claim/clm_596AA50FD9A5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000029/0001532176-15-000029-index.htm.","url":"https://asof.is/claim/clm_596AA50FD9A5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"194,643,000 United States dollar","status":"superseded","assertable":true,"id":"clm_596AA50FD9A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 344,859,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_5CB6EE7B0568, https://asof.is/claim/clm_5CB6EE7B0568, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000029/0001532176-15-000029-index.htm.","url":"https://asof.is/claim/clm_5CB6EE7B0568","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"344,859,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5CB6EE7B0568","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 3,338,458,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_8F821934137F, https://asof.is/claim/clm_8F821934137F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000029/0001532176-15-000029-index.htm.","url":"https://asof.is/claim/clm_8F821934137F","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"3,338,458,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F821934137F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 390,554,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_A572755A0D0E, https://asof.is/claim/clm_A572755A0D0E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000029/0001532176-15-000029-index.htm.","url":"https://asof.is/claim/clm_A572755A0D0E","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"390,554,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A572755A0D0E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 390,330,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_ECBF22AE9226, https://asof.is/claim/clm_ECBF22AE9226, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000029/0001532176-15-000029-index.htm.","url":"https://asof.is/claim/clm_ECBF22AE9226","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"390,330,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ECBF22AE9226","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 4,526,970,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_F1F28102C74A, https://asof.is/claim/clm_F1F28102C74A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000029/0001532176-15-000029-index.htm.","url":"https://asof.is/claim/clm_F1F28102C74A","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"4,526,970,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F1F28102C74A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,137,422,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_004FA2206A58, https://asof.is/claim/clm_004FA2206A58, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000037/0001532176-15-000037-index.htm.","url":"https://asof.is/claim/clm_004FA2206A58","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,137,422,000 United States dollar","status":"superseded","assertable":true,"id":"clm_004FA2206A58","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2015, filed 2015-11-04"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 392,422,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_013115790A9A, https://asof.is/claim/clm_013115790A9A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000037/0001532176-15-000037-index.htm.","url":"https://asof.is/claim/clm_013115790A9A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"392,422,000 United States dollar","status":"superseded","assertable":true,"id":"clm_013115790A9A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2015, filed 2015-11-04"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 654,587,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_9D0F451FC952, https://asof.is/claim/clm_9D0F451FC952, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000037/0001532176-15-000037-index.htm.","url":"https://asof.is/claim/clm_9D0F451FC952","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"654,587,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9D0F451FC952","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2015, filed 2015-11-04"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 210,398,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_A492FAF0038B, https://asof.is/claim/clm_A492FAF0038B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000037/0001532176-15-000037-index.htm.","url":"https://asof.is/claim/clm_A492FAF0038B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"210,398,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A492FAF0038B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2015, filed 2015-11-04"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 3,296,867,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_F47024193220, https://asof.is/claim/clm_F47024193220, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000037/0001532176-15-000037-index.htm.","url":"https://asof.is/claim/clm_F47024193220","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"3,296,867,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F47024193220","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2015, filed 2015-11-04"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 425,924,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_FBAC011B1148, https://asof.is/claim/clm_FBAC011B1148, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000037/0001532176-15-000037-index.htm.","url":"https://asof.is/claim/clm_FBAC011B1148","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"425,924,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FBAC011B1148","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2015, filed 2015-11-04"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 5,182,915,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_FC3EF79C19DA, https://asof.is/claim/clm_FC3EF79C19DA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000037/0001532176-15-000037-index.htm.","url":"https://asof.is/claim/clm_FC3EF79C19DA","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"5,182,915,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FC3EF79C19DA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2015, filed 2015-11-04"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 636,056,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_65C9343FBB71, https://asof.is/claim/clm_65C9343FBB71, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000045/0001532176-16-000045-index.htm.","url":"https://asof.is/claim/clm_65C9343FBB71","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"636,056,000 United States dollar","status":"superseded","assertable":true,"id":"clm_65C9343FBB71","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2015, filed 2016-02-11"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 1,251,916,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_83526134FED4, https://asof.is/claim/clm_83526134FED4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000045/0001532176-16-000045-index.htm.","url":"https://asof.is/claim/clm_83526134FED4","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"1,251,916,000 United States dollar","status":"superseded","assertable":true,"id":"clm_83526134FED4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2015, filed 2016-02-11"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 5,609,132,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_AE851A5E41A1, https://asof.is/claim/clm_AE851A5E41A1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000045/0001532176-16-000045-index.htm.","url":"https://asof.is/claim/clm_AE851A5E41A1","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"5,609,132,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AE851A5E41A1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2015, filed 2016-02-11"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 1,620,577,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_C192D950A63C, https://asof.is/claim/clm_C192D950A63C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000045/0001532176-16-000045-index.htm.","url":"https://asof.is/claim/clm_C192D950A63C","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"1,620,577,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C192D950A63C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2015, filed 2016-02-11"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 4,103,728,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_DA3C150446BB, https://asof.is/claim/clm_DA3C150446BB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000045/0001532176-16-000045-index.htm.","url":"https://asof.is/claim/clm_DA3C150446BB","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"4,103,728,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DA3C150446BB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2015, filed 2016-02-11"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 809,102,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_E1A1DD321AA2, https://asof.is/claim/clm_E1A1DD321AA2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000045/0001532176-16-000045-index.htm.","url":"https://asof.is/claim/clm_E1A1DD321AA2","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"809,102,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E1A1DD321AA2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2015, filed 2016-02-11"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 3,654,837,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_E4E81E6E76BC, https://asof.is/claim/clm_E4E81E6E76BC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000045/0001532176-16-000045-index.htm.","url":"https://asof.is/claim/clm_E4E81E6E76BC","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"3,654,837,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E4E81E6E76BC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2015, filed 2016-02-11"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 604,214,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_0DC1B23A3E38, https://asof.is/claim/clm_0DC1B23A3E38, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000055/0001532176-16-000055-index.htm.","url":"https://asof.is/claim/clm_0DC1B23A3E38","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"604,214,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0DC1B23A3E38","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2016, filed 2016-05-05"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 5,904,460,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_27428FFDF264, https://asof.is/claim/clm_27428FFDF264, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000055/0001532176-16-000055-index.htm.","url":"https://asof.is/claim/clm_27428FFDF264","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"5,904,460,000 United States dollar","status":"superseded","assertable":true,"id":"clm_27428FFDF264","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2016, filed 2016-05-05"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 329,308,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_6493D88744E3, https://asof.is/claim/clm_6493D88744E3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000055/0001532176-16-000055-index.htm.","url":"https://asof.is/claim/clm_6493D88744E3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"329,308,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6493D88744E3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-05"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 3,765,082,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_6F441A6B882E, https://asof.is/claim/clm_6F441A6B882E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000055/0001532176-16-000055-index.htm.","url":"https://asof.is/claim/clm_6F441A6B882E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"3,765,082,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6F441A6B882E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2016, filed 2016-05-05"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 470,112,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_82D4EB6D361F, https://asof.is/claim/clm_82D4EB6D361F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000055/0001532176-16-000055-index.htm.","url":"https://asof.is/claim/clm_82D4EB6D361F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"470,112,000 United States dollar","status":"superseded","assertable":true,"id":"clm_82D4EB6D361F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2016, filed 2016-05-05"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 165,736,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_8997B789C3CE, https://asof.is/claim/clm_8997B789C3CE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000055/0001532176-16-000055-index.htm.","url":"https://asof.is/claim/clm_8997B789C3CE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"165,736,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8997B789C3CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-05"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,200,849,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_A146DEFD4AD2, https://asof.is/claim/clm_A146DEFD4AD2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000055/0001532176-16-000055-index.htm.","url":"https://asof.is/claim/clm_A146DEFD4AD2","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,200,849,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A146DEFD4AD2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2016, filed 2016-05-05"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 559,930,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_61FB221F52F9, https://asof.is/claim/clm_61FB221F52F9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000067/0001532176-16-000067-index.htm.","url":"https://asof.is/claim/clm_61FB221F52F9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"559,930,000 United States dollar","status":"superseded","assertable":true,"id":"clm_61FB221F52F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2016, filed 2016-08-04"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,212,629,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_6B4AC1C07D2A, https://asof.is/claim/clm_6B4AC1C07D2A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000067/0001532176-16-000067-index.htm.","url":"https://asof.is/claim/clm_6B4AC1C07D2A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,212,629,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6B4AC1C07D2A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2016, filed 2016-08-04"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 291,628,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_7203835AF9D6, https://asof.is/claim/clm_7203835AF9D6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000067/0001532176-16-000067-index.htm.","url":"https://asof.is/claim/clm_7203835AF9D6","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"291,628,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7203835AF9D6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2016, filed 2016-08-04"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 4,076,506,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_76A176931199, https://asof.is/claim/clm_76A176931199, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000067/0001532176-16-000067-index.htm.","url":"https://asof.is/claim/clm_76A176931199","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,076,506,000 United States dollar","status":"superseded","assertable":true,"id":"clm_76A176931199","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2016, filed 2016-08-04"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 646,508,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_7F0BA57185F7, https://asof.is/claim/clm_7F0BA57185F7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000067/0001532176-16-000067-index.htm.","url":"https://asof.is/claim/clm_7F0BA57185F7","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"646,508,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7F0BA57185F7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2016, filed 2016-08-04"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 196,218,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_A69584A31BB4, https://asof.is/claim/clm_A69584A31BB4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000067/0001532176-16-000067-index.htm.","url":"https://asof.is/claim/clm_A69584A31BB4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"196,218,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A69584A31BB4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2016, filed 2016-08-04"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 6,204,906,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_FFE019961773, https://asof.is/claim/clm_FFE019961773, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000067/0001532176-16-000067-index.htm.","url":"https://asof.is/claim/clm_FFE019961773","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"6,204,906,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FFE019961773","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2016, filed 2016-08-04"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 264,804,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_688F0D43862F, https://asof.is/claim/clm_688F0D43862F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000082/0001532176-16-000082-index.htm.","url":"https://asof.is/claim/clm_688F0D43862F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"264,804,000 United States dollar","status":"superseded","assertable":true,"id":"clm_688F0D43862F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2016, filed 2016-11-04"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 362,802,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_7149A1CA2203, https://asof.is/claim/clm_7149A1CA2203, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000082/0001532176-16-000082-index.htm.","url":"https://asof.is/claim/clm_7149A1CA2203","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"362,802,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7149A1CA2203","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2016, filed 2016-11-04"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 543,047,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_B963E3479652, https://asof.is/claim/clm_B963E3479652, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000082/0001532176-16-000082-index.htm.","url":"https://asof.is/claim/clm_B963E3479652","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"543,047,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B963E3479652","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2016, filed 2016-11-04"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 4,491,247,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_BD93EEA985A9, https://asof.is/claim/clm_BD93EEA985A9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000082/0001532176-16-000082-index.htm.","url":"https://asof.is/claim/clm_BD93EEA985A9","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,491,247,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BD93EEA985A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2016, filed 2016-11-04"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,220,122,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_C7626FBBC9B4, https://asof.is/claim/clm_C7626FBBC9B4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000082/0001532176-16-000082-index.htm.","url":"https://asof.is/claim/clm_C7626FBBC9B4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,220,122,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C7626FBBC9B4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2016, filed 2016-11-04"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 6,828,019,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_D5B8CC2A7197, https://asof.is/claim/clm_D5B8CC2A7197, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000082/0001532176-16-000082-index.htm.","url":"https://asof.is/claim/clm_D5B8CC2A7197","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"6,828,019,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D5B8CC2A7197","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2016, filed 2016-11-04"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 920,359,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_DF775611DD53, https://asof.is/claim/clm_DF775611DD53, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217616000082/0001532176-16-000082-index.htm.","url":"https://asof.is/claim/clm_DF775611DD53","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"920,359,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DF775611DD53","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2016, filed 2016-11-04"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 535,203,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_06AB5E3637AD, https://asof.is/claim/clm_06AB5E3637AD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000008/0001532176-17-000008-index.htm.","url":"https://asof.is/claim/clm_06AB5E3637AD","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"535,203,000 United States dollar","status":"superseded","assertable":true,"id":"clm_06AB5E3637AD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2016, filed 2017-02-09"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 2,052,295,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_0710977E9941, https://asof.is/claim/clm_0710977E9941, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000008/0001532176-17-000008-index.htm.","url":"https://asof.is/claim/clm_0710977E9941","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,052,295,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0710977E9941","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2016, filed 2017-02-09"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 1,330,741,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_1B4689E225C8, https://asof.is/claim/clm_1B4689E225C8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000008/0001532176-17-000008-index.htm.","url":"https://asof.is/claim/clm_1B4689E225C8","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"1,330,741,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1B4689E225C8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2016, filed 2017-02-09"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 6,973,466,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_203164BC0145, https://asof.is/claim/clm_203164BC0145, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000008/0001532176-17-000008-index.htm.","url":"https://asof.is/claim/clm_203164BC0145","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"6,973,466,000 United States dollar","status":"superseded","assertable":true,"id":"clm_203164BC0145","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2016, filed 2017-02-09"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 4,449,245,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_33C916697C43, https://asof.is/claim/clm_33C916697C43, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000008/0001532176-17-000008-index.htm.","url":"https://asof.is/claim/clm_33C916697C43","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,449,245,000 United States dollar","status":"superseded","assertable":true,"id":"clm_33C916697C43","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2016, filed 2017-02-09"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 895,522,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_AFF68BBC35BE, https://asof.is/claim/clm_AFF68BBC35BE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000008/0001532176-17-000008-index.htm.","url":"https://asof.is/claim/clm_AFF68BBC35BE","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"895,522,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AFF68BBC35BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2016, filed 2017-02-09"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 4,860,427,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_CF6C0D5C4B30, https://asof.is/claim/clm_CF6C0D5C4B30, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000008/0001532176-17-000008-index.htm.","url":"https://asof.is/claim/clm_CF6C0D5C4B30","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"4,860,427,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CF6C0D5C4B30","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2016, filed 2017-02-09"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 430,542,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_0981CA086973, https://asof.is/claim/clm_0981CA086973, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000017/0001532176-17-000017-index.htm.","url":"https://asof.is/claim/clm_0981CA086973","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"430,542,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0981CA086973","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-04"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 507,435,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_47AF0CE8CA36, https://asof.is/claim/clm_47AF0CE8CA36, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000017/0001532176-17-000017-index.htm.","url":"https://asof.is/claim/clm_47AF0CE8CA36","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"507,435,000 United States dollar","status":"superseded","assertable":true,"id":"clm_47AF0CE8CA36","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2017, filed 2017-05-04"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,318,991,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_5AF2197029A2, https://asof.is/claim/clm_5AF2197029A2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000017/0001532176-17-000017-index.htm.","url":"https://asof.is/claim/clm_5AF2197029A2","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,318,991,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5AF2197029A2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2017, filed 2017-05-04"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 4,866,021,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_7D612B392881, https://asof.is/claim/clm_7D612B392881, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000017/0001532176-17-000017-index.htm.","url":"https://asof.is/claim/clm_7D612B392881","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,866,021,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7D612B392881","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2017, filed 2017-05-04"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 7,817,365,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_9994303F1EB2, https://asof.is/claim/clm_9994303F1EB2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000017/0001532176-17-000017-index.htm.","url":"https://asof.is/claim/clm_9994303F1EB2","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"7,817,365,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9994303F1EB2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2017, filed 2017-05-04"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 248,931,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_9B839ECAF179, https://asof.is/claim/clm_9B839ECAF179, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000017/0001532176-17-000017-index.htm.","url":"https://asof.is/claim/clm_9B839ECAF179","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"248,931,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9B839ECAF179","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-04"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 811,773,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_FA2D5FA2C813, https://asof.is/claim/clm_FA2D5FA2C813, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000017/0001532176-17-000017-index.htm.","url":"https://asof.is/claim/clm_FA2D5FA2C813","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"811,773,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FA2D5FA2C813","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2017, filed 2017-05-04"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 744,313,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_0922596878B8, https://asof.is/claim/clm_0922596878B8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000027/0001532176-17-000027-index.htm.","url":"https://asof.is/claim/clm_0922596878B8","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"744,313,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0922596878B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2017, filed 2017-08-03"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 550,312,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_3C35AE6BEE76, https://asof.is/claim/clm_3C35AE6BEE76, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000027/0001532176-17-000027-index.htm.","url":"https://asof.is/claim/clm_3C35AE6BEE76","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"550,312,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3C35AE6BEE76","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2017, filed 2017-08-03"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 5,520,738,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_A552A047999A, https://asof.is/claim/clm_A552A047999A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000027/0001532176-17-000027-index.htm.","url":"https://asof.is/claim/clm_A552A047999A","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"5,520,738,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A552A047999A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2017, filed 2017-08-03"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 8,106,373,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_A8323F1BC4B3, https://asof.is/claim/clm_A8323F1BC4B3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000027/0001532176-17-000027-index.htm.","url":"https://asof.is/claim/clm_A8323F1BC4B3","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"8,106,373,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A8323F1BC4B3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2017, filed 2017-08-03"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,470,116,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_E83335CDCC26, https://asof.is/claim/clm_E83335CDCC26, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000027/0001532176-17-000027-index.htm.","url":"https://asof.is/claim/clm_E83335CDCC26","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,470,116,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E83335CDCC26","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2017, filed 2017-08-03"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 509,975,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_F6A5C3C217BB, https://asof.is/claim/clm_F6A5C3C217BB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000027/0001532176-17-000027-index.htm.","url":"https://asof.is/claim/clm_F6A5C3C217BB","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"509,975,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F6A5C3C217BB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2017, filed 2017-08-03"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 387,744,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_FDD921AB38B0, https://asof.is/claim/clm_FDD921AB38B0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000027/0001532176-17-000027-index.htm.","url":"https://asof.is/claim/clm_FDD921AB38B0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"387,744,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FDD921AB38B0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2017, filed 2017-08-03"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 559,926,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_0068759D81FA, https://asof.is/claim/clm_0068759D81FA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000034/0001532176-17-000034-index.htm.","url":"https://asof.is/claim/clm_0068759D81FA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"559,926,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0068759D81FA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2017, filed 2017-11-08"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,500,673,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_13C3FB7E9C67, https://asof.is/claim/clm_13C3FB7E9C67, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000034/0001532176-17-000034-index.htm.","url":"https://asof.is/claim/clm_13C3FB7E9C67","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,500,673,000 United States dollar","status":"superseded","assertable":true,"id":"clm_13C3FB7E9C67","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2017, filed 2017-11-08"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 8,701,215,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_492409E212E4, https://asof.is/claim/clm_492409E212E4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000034/0001532176-17-000034-index.htm.","url":"https://asof.is/claim/clm_492409E212E4","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"8,701,215,000 United States dollar","status":"superseded","assertable":true,"id":"clm_492409E212E4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2017, filed 2017-11-08"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 792,065,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_8AF6FE5A4F7D, https://asof.is/claim/clm_8AF6FE5A4F7D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000034/0001532176-17-000034-index.htm.","url":"https://asof.is/claim/clm_8AF6FE5A4F7D","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"792,065,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8AF6FE5A4F7D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2017, filed 2017-11-08"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 529,749,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_A9BE529B3D7A, https://asof.is/claim/clm_A9BE529B3D7A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000034/0001532176-17-000034-index.htm.","url":"https://asof.is/claim/clm_A9BE529B3D7A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"529,749,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A9BE529B3D7A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2017, filed 2017-11-08"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 6,051,593,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_DD3546A9D128, https://asof.is/claim/clm_DD3546A9D128, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000034/0001532176-17-000034-index.htm.","url":"https://asof.is/claim/clm_DD3546A9D128","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"6,051,593,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DD3546A9D128","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2017, filed 2017-11-08"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 388,317,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_EE7D9E55E7D2, https://asof.is/claim/clm_EE7D9E55E7D2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217617000034/0001532176-17-000034-index.htm.","url":"https://asof.is/claim/clm_EE7D9E55E7D2","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"388,317,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EE7D9E55E7D2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2017, filed 2017-11-08"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 5,872,227,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_246434942F91, https://asof.is/claim/clm_246434942F91, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000013/0001532176-18-000013-index.htm.","url":"https://asof.is/claim/clm_246434942F91","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"5,872,227,000 United States dollar","status":"superseded","assertable":true,"id":"clm_246434942F91","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2017, filed 2018-02-08"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 2,075,142,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_26FF10B62963, https://asof.is/claim/clm_26FF10B62963, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000013/0001532176-18-000013-index.htm.","url":"https://asof.is/claim/clm_26FF10B62963","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,075,142,000 United States dollar","status":"superseded","assertable":true,"id":"clm_26FF10B62963","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2017, filed 2018-02-08"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 6,144,078,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_5918225890D8, https://asof.is/claim/clm_5918225890D8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000013/0001532176-18-000013-index.htm.","url":"https://asof.is/claim/clm_5918225890D8","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"6,144,078,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5918225890D8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2017, filed 2018-02-08"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 2,079,591,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_C3B4B1FC7983, https://asof.is/claim/clm_C3B4B1FC7983, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000013/0001532176-18-000013-index.htm.","url":"https://asof.is/claim/clm_C3B4B1FC7983","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"2,079,591,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C3B4B1FC7983","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2017, filed 2018-02-08"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 1,198,511,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_DC0177CB2929, https://asof.is/claim/clm_DC0177CB2929, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000013/0001532176-18-000013-index.htm.","url":"https://asof.is/claim/clm_DC0177CB2929","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"1,198,511,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC0177CB2929","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2017, filed 2018-02-08"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 8,764,286,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_E5F3BEB8DB99, https://asof.is/claim/clm_E5F3BEB8DB99, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000013/0001532176-18-000013-index.htm.","url":"https://asof.is/claim/clm_E5F3BEB8DB99","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"8,764,286,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E5F3BEB8DB99","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2017, filed 2018-02-08"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 812,733,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_E98C18EDD84F, https://asof.is/claim/clm_E98C18EDD84F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000013/0001532176-18-000013-index.htm.","url":"https://asof.is/claim/clm_E98C18EDD84F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"812,733,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E98C18EDD84F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2017, filed 2018-02-08"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 498,586,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_4BE823A99904, https://asof.is/claim/clm_4BE823A99904, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000020/0001532176-18-000020-index.htm.","url":"https://asof.is/claim/clm_4BE823A99904","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"498,586,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4BE823A99904","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2018, filed 2018-05-03"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,511,485,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_7E235362DFEC, https://asof.is/claim/clm_7E235362DFEC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000020/0001532176-18-000020-index.htm.","url":"https://asof.is/claim/clm_7E235362DFEC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,511,485,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7E235362DFEC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2018, filed 2018-05-03"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 477,980,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_8ABE9095142D, https://asof.is/claim/clm_8ABE9095142D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000020/0001532176-18-000020-index.htm.","url":"https://asof.is/claim/clm_8ABE9095142D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"477,980,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8ABE9095142D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2018, filed 2018-05-03"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 567,231,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_8FA9C48DB5EF, https://asof.is/claim/clm_8FA9C48DB5EF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000020/0001532176-18-000020-index.htm.","url":"https://asof.is/claim/clm_8FA9C48DB5EF","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"567,231,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8FA9C48DB5EF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2018, filed 2018-05-03"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 6,567,644,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_A1D158DEA4C8, https://asof.is/claim/clm_A1D158DEA4C8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000020/0001532176-18-000020-index.htm.","url":"https://asof.is/claim/clm_A1D158DEA4C8","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"6,567,644,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A1D158DEA4C8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2018, filed 2018-05-03"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,019,491,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_D7FA3AE5790E, https://asof.is/claim/clm_D7FA3AE5790E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000020/0001532176-18-000020-index.htm.","url":"https://asof.is/claim/clm_D7FA3AE5790E","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,019,491,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D7FA3AE5790E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2018, filed 2018-05-03"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 9,372,696,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_E21934E189C3, https://asof.is/claim/clm_E21934E189C3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000020/0001532176-18-000020-index.htm.","url":"https://asof.is/claim/clm_E21934E189C3","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"9,372,696,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E21934E189C3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2018, filed 2018-05-03"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 7,186,426,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_23FD05B1D458, https://asof.is/claim/clm_23FD05B1D458, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000028/0001532176-18-000028-index.htm.","url":"https://asof.is/claim/clm_23FD05B1D458","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"7,186,426,000 United States dollar","status":"superseded","assertable":true,"id":"clm_23FD05B1D458","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2018, filed 2018-08-02"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,608,022,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_31D8E26EE368, https://asof.is/claim/clm_31D8E26EE368, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000028/0001532176-18-000028-index.htm.","url":"https://asof.is/claim/clm_31D8E26EE368","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,608,022,000 United States dollar","status":"superseded","assertable":true,"id":"clm_31D8E26EE368","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2018, filed 2018-08-02"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 551,412,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_3E424C4A1EAC, https://asof.is/claim/clm_3E424C4A1EAC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000028/0001532176-18-000028-index.htm.","url":"https://asof.is/claim/clm_3E424C4A1EAC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"551,412,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3E424C4A1EAC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2018, filed 2018-08-02"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 917,876,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_4718E4C5B45C, https://asof.is/claim/clm_4718E4C5B45C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000028/0001532176-18-000028-index.htm.","url":"https://asof.is/claim/clm_4718E4C5B45C","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"917,876,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4718E4C5B45C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2018, filed 2018-08-02"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 622,188,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_932289F9A641, https://asof.is/claim/clm_932289F9A641, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000028/0001532176-18-000028-index.htm.","url":"https://asof.is/claim/clm_932289F9A641","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"622,188,000 United States dollar","status":"superseded","assertable":true,"id":"clm_932289F9A641","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2018, filed 2018-08-02"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 529,289,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_A105D8C47C87, https://asof.is/claim/clm_A105D8C47C87, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000028/0001532176-18-000028-index.htm.","url":"https://asof.is/claim/clm_A105D8C47C87","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"529,289,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A105D8C47C87","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2018, filed 2018-08-02"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 9,951,980,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_C84D8DF1209C, https://asof.is/claim/clm_C84D8DF1209C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000028/0001532176-18-000028-index.htm.","url":"https://asof.is/claim/clm_C84D8DF1209C","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"9,951,980,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C84D8DF1209C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2018, filed 2018-08-02"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 626,923,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_56C5E89651F4, https://asof.is/claim/clm_56C5E89651F4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000036/0001532176-18-000036-index.htm.","url":"https://asof.is/claim/clm_56C5E89651F4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"626,923,000 United States dollar","status":"superseded","assertable":true,"id":"clm_56C5E89651F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 594,655,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_5878C421FA89, https://asof.is/claim/clm_5878C421FA89, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000036/0001532176-18-000036-index.htm.","url":"https://asof.is/claim/clm_5878C421FA89","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"594,655,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5878C421FA89","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 10,805,613,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_598EFC61CEA9, https://asof.is/claim/clm_598EFC61CEA9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000036/0001532176-18-000036-index.htm.","url":"https://asof.is/claim/clm_598EFC61CEA9","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"10,805,613,000 United States dollar","status":"superseded","assertable":true,"id":"clm_598EFC61CEA9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,663,496,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_747F97C3BEDC, https://asof.is/claim/clm_747F97C3BEDC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000036/0001532176-18-000036-index.htm.","url":"https://asof.is/claim/clm_747F97C3BEDC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,663,496,000 United States dollar","status":"superseded","assertable":true,"id":"clm_747F97C3BEDC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 7,868,300,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_A1DD99D38B48, https://asof.is/claim/clm_A1DD99D38B48, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000036/0001532176-18-000036-index.htm.","url":"https://asof.is/claim/clm_A1DD99D38B48","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"7,868,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A1DD99D38B48","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 556,972,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_B522A588AB4A, https://asof.is/claim/clm_B522A588AB4A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000036/0001532176-18-000036-index.htm.","url":"https://asof.is/claim/clm_B522A588AB4A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"556,972,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B522A588AB4A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,087,843,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_F025AB0020A5, https://asof.is/claim/clm_F025AB0020A5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000036/0001532176-18-000036-index.htm.","url":"https://asof.is/claim/clm_F025AB0020A5","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,087,843,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F025AB0020A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 6,710,800,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_002F725B2106, https://asof.is/claim/clm_002F725B2106, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000009/0001532176-19-000009-index.htm.","url":"https://asof.is/claim/clm_002F725B2106","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"6,710,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_002F725B2106","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2018, filed 2019-02-07"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 2,186,100,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_266453DBFA15, https://asof.is/claim/clm_266453DBFA15, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000009/0001532176-19-000009-index.htm.","url":"https://asof.is/claim/clm_266453DBFA15","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,186,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_266453DBFA15","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2018, filed 2019-02-07"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 8,757,300,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_5D32FAC7392D, https://asof.is/claim/clm_5D32FAC7392D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000009/0001532176-19-000009-index.htm.","url":"https://asof.is/claim/clm_5D32FAC7392D","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"8,757,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5D32FAC7392D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2018, filed 2019-02-07"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 11,734,500,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_B7C53A5B665E, https://asof.is/claim/clm_B7C53A5B665E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000009/0001532176-19-000009-index.htm.","url":"https://asof.is/claim/clm_B7C53A5B665E","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"11,734,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B7C53A5B665E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2018, filed 2019-02-07"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 2,534,400,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_B9BD4A691253, https://asof.is/claim/clm_B9BD4A691253, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000009/0001532176-19-000009-index.htm.","url":"https://asof.is/claim/clm_B9BD4A691253","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"2,534,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B9BD4A691253","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2018, filed 2019-02-07"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,467,700,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_DA2FDFFFBAB2, https://asof.is/claim/clm_DA2FDFFFBAB2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000009/0001532176-19-000009-index.htm.","url":"https://asof.is/claim/clm_DA2FDFFFBAB2","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,467,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DA2FDFFFBAB2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2018, filed 2019-02-07"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 2,444,400,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_FCBDA03CE99C, https://asof.is/claim/clm_FCBDA03CE99C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000009/0001532176-19-000009-index.htm.","url":"https://asof.is/claim/clm_FCBDA03CE99C","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"2,444,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FCBDA03CE99C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2018, filed 2019-02-07"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 12,854,800,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_11C939138FE3, https://asof.is/claim/clm_11C939138FE3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000017/0001532176-19-000017-index.htm.","url":"https://asof.is/claim/clm_11C939138FE3","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"12,854,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_11C939138FE3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2019, filed 2019-05-07"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,711,800,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_47864C915D20, https://asof.is/claim/clm_47864C915D20, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000017/0001532176-19-000017-index.htm.","url":"https://asof.is/claim/clm_47864C915D20","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,711,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_47864C915D20","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2019, filed 2019-05-07"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,708,500,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_B732DAD499F6, https://asof.is/claim/clm_B732DAD499F6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000017/0001532176-19-000017-index.htm.","url":"https://asof.is/claim/clm_B732DAD499F6","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,708,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B732DAD499F6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2019, filed 2019-05-07"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 461,100,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_BD7F43D94B6B, https://asof.is/claim/clm_BD7F43D94B6B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000017/0001532176-19-000017-index.htm.","url":"https://asof.is/claim/clm_BD7F43D94B6B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"461,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BD7F43D94B6B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-07"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 480,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_D84361499AD2, https://asof.is/claim/clm_D84361499AD2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000017/0001532176-19-000017-index.htm.","url":"https://asof.is/claim/clm_D84361499AD2","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"480,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D84361499AD2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-07"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 9,444,700,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_EA1240C78E2F, https://asof.is/claim/clm_EA1240C78E2F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000017/0001532176-19-000017-index.htm.","url":"https://asof.is/claim/clm_EA1240C78E2F","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"9,444,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EA1240C78E2F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2019, filed 2019-05-07"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 641,800,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_EB7DE0743EFE, https://asof.is/claim/clm_EB7DE0743EFE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000017/0001532176-19-000017-index.htm.","url":"https://asof.is/claim/clm_EB7DE0743EFE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"641,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EB7DE0743EFE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2019, filed 2019-05-07"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 13,173,600,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_1663DBFF8E0F, https://asof.is/claim/clm_1663DBFF8E0F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000026/0001532176-19-000026-index.htm.","url":"https://asof.is/claim/clm_1663DBFF8E0F","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"13,173,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1663DBFF8E0F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2019, filed 2019-08-06"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,048,300,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_1EB9C85348DD, https://asof.is/claim/clm_1EB9C85348DD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000026/0001532176-19-000026-index.htm.","url":"https://asof.is/claim/clm_1EB9C85348DD","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,048,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1EB9C85348DD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2019, filed 2019-08-06"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,045,500,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_81A51A91E316, https://asof.is/claim/clm_81A51A91E316, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000026/0001532176-19-000026-index.htm.","url":"https://asof.is/claim/clm_81A51A91E316","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,045,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_81A51A91E316","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2019, filed 2019-08-06"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 193,100,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_9FCE1A38D2F3, https://asof.is/claim/clm_9FCE1A38D2F3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000026/0001532176-19-000026-index.htm.","url":"https://asof.is/claim/clm_9FCE1A38D2F3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"193,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9FCE1A38D2F3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2019, filed 2019-08-06"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 315,600,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_A67CDBAE0DFB, https://asof.is/claim/clm_A67CDBAE0DFB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000026/0001532176-19-000026-index.htm.","url":"https://asof.is/claim/clm_A67CDBAE0DFB","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"315,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A67CDBAE0DFB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2019, filed 2019-08-06"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 9,755,900,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_A9EA52B10DF1, https://asof.is/claim/clm_A9EA52B10DF1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000026/0001532176-19-000026-index.htm.","url":"https://asof.is/claim/clm_A9EA52B10DF1","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"9,755,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A9EA52B10DF1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2019, filed 2019-08-06"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,933,700,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_D84F29A094C8, https://asof.is/claim/clm_D84F29A094C8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000026/0001532176-19-000026-index.htm.","url":"https://asof.is/claim/clm_D84F29A094C8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,933,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D84F29A094C8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2019, filed 2019-08-06"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 738,500,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_0355C334B021, https://asof.is/claim/clm_0355C334B021, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000034/0001532176-19-000034-index.htm.","url":"https://asof.is/claim/clm_0355C334B021","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"738,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0355C334B021","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2019, filed 2019-11-05"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 10,504,400,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_0B7B84608335, https://asof.is/claim/clm_0B7B84608335, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000034/0001532176-19-000034-index.htm.","url":"https://asof.is/claim/clm_0B7B84608335","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"10,504,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0B7B84608335","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2019, filed 2019-11-05"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 669,600,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_1FB3AA7D1659, https://asof.is/claim/clm_1FB3AA7D1659, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000034/0001532176-19-000034-index.htm.","url":"https://asof.is/claim/clm_1FB3AA7D1659","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"669,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1FB3AA7D1659","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2019, filed 2019-11-05"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,384,800,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_73EBCD32CE58, https://asof.is/claim/clm_73EBCD32CE58, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000034/0001532176-19-000034-index.htm.","url":"https://asof.is/claim/clm_73EBCD32CE58","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,384,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_73EBCD32CE58","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2019, filed 2019-11-05"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 663,400,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_9A19CD3DE19C, https://asof.is/claim/clm_9A19CD3DE19C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000034/0001532176-19-000034-index.htm.","url":"https://asof.is/claim/clm_9A19CD3DE19C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"663,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9A19CD3DE19C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2019, filed 2019-11-05"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 13,939,300,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_BDCB60E4D48C, https://asof.is/claim/clm_BDCB60E4D48C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000034/0001532176-19-000034-index.htm.","url":"https://asof.is/claim/clm_BDCB60E4D48C","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"13,939,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BDCB60E4D48C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2019, filed 2019-11-05"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 2,048,400,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_F3847C54AA19, https://asof.is/claim/clm_F3847C54AA19, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217619000034/0001532176-19-000034-index.htm.","url":"https://asof.is/claim/clm_F3847C54AA19","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"2,048,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F3847C54AA19","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2019, filed 2019-11-05"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 2,209,800,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_1E47F3A48E8B, https://asof.is/claim/clm_1E47F3A48E8B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217620000008/0001532176-20-000008-index.htm.","url":"https://asof.is/claim/clm_1E47F3A48E8B","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"2,209,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1E47F3A48E8B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2019, filed 2020-02-07"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 2,115,800,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_272E08FDAC9C, https://asof.is/claim/clm_272E08FDAC9C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217620000008/0001532176-20-000008-index.htm.","url":"https://asof.is/claim/clm_272E08FDAC9C","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"2,115,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_272E08FDAC9C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2019, filed 2020-02-07"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 11,089,700,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_32CFF858652E, https://asof.is/claim/clm_32CFF858652E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217620000008/0001532176-20-000008-index.htm.","url":"https://asof.is/claim/clm_32CFF858652E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"11,089,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_32CFF858652E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2019, filed 2020-02-07"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 3,036,600,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_45C96BE1D685, https://asof.is/claim/clm_45C96BE1D685, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217620000008/0001532176-20-000008-index.htm.","url":"https://asof.is/claim/clm_45C96BE1D685","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"3,036,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_45C96BE1D685","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2019, filed 2020-02-07"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 7,863,400,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_98C359CB4FBA, https://asof.is/claim/clm_98C359CB4FBA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217620000008/0001532176-20-000008-index.htm.","url":"https://asof.is/claim/clm_98C359CB4FBA","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"7,863,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_98C359CB4FBA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2019, filed 2020-02-07"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 14,805,200,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_A8B1190C6433, https://asof.is/claim/clm_A8B1190C6433, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217620000008/0001532176-20-000008-index.htm.","url":"https://asof.is/claim/clm_A8B1190C6433","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"14,805,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A8B1190C6433","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2019, filed 2020-02-07"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,617,800,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_B770510DD1DE, https://asof.is/claim/clm_B770510DD1DE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217620000008/0001532176-20-000008-index.htm.","url":"https://asof.is/claim/clm_B770510DD1DE","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,617,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B770510DD1DE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2019, filed 2020-02-07"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,828,200,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_0BEF5E393370, https://asof.is/claim/clm_0BEF5E393370, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000011/0001804220-20-000011-index.htm.","url":"https://asof.is/claim/clm_0BEF5E393370","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,828,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0BEF5E393370","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2020, filed 2020-05-05"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 15,757,500,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_1526DF06387A, https://asof.is/claim/clm_1526DF06387A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000011/0001804220-20-000011-index.htm.","url":"https://asof.is/claim/clm_1526DF06387A","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"15,757,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1526DF06387A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2020, filed 2020-05-05"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,208,200,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_31B1EF0C9CA5, https://asof.is/claim/clm_31B1EF0C9CA5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000011/0001804220-20-000011-index.htm.","url":"https://asof.is/claim/clm_31B1EF0C9CA5","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,208,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_31B1EF0C9CA5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2020, filed 2020-05-05"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 583,900,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_4E4440D647F0, https://asof.is/claim/clm_4E4440D647F0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000011/0001804220-20-000011-index.htm.","url":"https://asof.is/claim/clm_4E4440D647F0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"583,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4E4440D647F0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2020, filed 2020-05-05"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 624,600,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_61AB4AC8223A, https://asof.is/claim/clm_61AB4AC8223A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000011/0001804220-20-000011-index.htm.","url":"https://asof.is/claim/clm_61AB4AC8223A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"624,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_61AB4AC8223A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-05"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 700,100,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_D51C41802591, https://asof.is/claim/clm_D51C41802591, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000011/0001804220-20-000011-index.htm.","url":"https://asof.is/claim/clm_D51C41802591","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"700,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D51C41802591","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-05"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 12,133,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_FFF6E94E2B98, https://asof.is/claim/clm_FFF6E94E2B98, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000011/0001804220-20-000011-index.htm.","url":"https://asof.is/claim/clm_FFF6E94E2B98","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"12,133,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FFF6E94E2B98","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2020, filed 2020-05-05"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 9,057,400,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_2CC38605C128, https://asof.is/claim/clm_2CC38605C128, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000022/0001804220-20-000022-index.htm.","url":"https://asof.is/claim/clm_2CC38605C128","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"9,057,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2CC38605C128","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2020, filed 2020-08-05"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,992,200,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_38840DD0F1A6, https://asof.is/claim/clm_38840DD0F1A6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000022/0001804220-20-000022-index.htm.","url":"https://asof.is/claim/clm_38840DD0F1A6","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,992,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_38840DD0F1A6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2020, filed 2020-08-05"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 14,428,700,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_644D82754410, https://asof.is/claim/clm_644D82754410, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000022/0001804220-20-000022-index.htm.","url":"https://asof.is/claim/clm_644D82754410","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"14,428,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_644D82754410","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2020, filed 2020-08-05"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 897,300,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_A816A2A4556B, https://asof.is/claim/clm_A816A2A4556B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000022/0001804220-20-000022-index.htm.","url":"https://asof.is/claim/clm_A816A2A4556B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"897,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A816A2A4556B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2020, filed 2020-08-05"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 1,952,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_B16B9D90B428, https://asof.is/claim/clm_B16B9D90B428, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000022/0001804220-20-000022-index.htm.","url":"https://asof.is/claim/clm_B16B9D90B428","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"1,952,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B16B9D90B428","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2020, filed 2020-08-05"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 656,400,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_C3A6CADA4F04, https://asof.is/claim/clm_C3A6CADA4F04, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000022/0001804220-20-000022-index.htm.","url":"https://asof.is/claim/clm_C3A6CADA4F04","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"656,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C3A6CADA4F04","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2020, filed 2020-08-05"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 722,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_E051418D4ABD, https://asof.is/claim/clm_E051418D4ABD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000022/0001804220-20-000022-index.htm.","url":"https://asof.is/claim/clm_E051418D4ABD","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"722,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E051418D4ABD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2020, filed 2020-08-05"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,573,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_0151EA6FB45E, https://asof.is/claim/clm_0151EA6FB45E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000030/0001804220-20-000030-index.htm.","url":"https://asof.is/claim/clm_0151EA6FB45E","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,573,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0151EA6FB45E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 10,125,500,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_3A63F9598C82, https://asof.is/claim/clm_3A63F9598C82, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000030/0001804220-20-000030-index.htm.","url":"https://asof.is/claim/clm_3A63F9598C82","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"10,125,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3A63F9598C82","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 16,084,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_8D47F8B72C13, https://asof.is/claim/clm_8D47F8B72C13, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000030/0001804220-20-000030-index.htm.","url":"https://asof.is/claim/clm_8D47F8B72C13","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"16,084,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8D47F8B72C13","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 684,600,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_A4EE4D07A0E8, https://asof.is/claim/clm_A4EE4D07A0E8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000030/0001804220-20-000030-index.htm.","url":"https://asof.is/claim/clm_A4EE4D07A0E8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"684,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A4EE4D07A0E8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 2,294,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_E888336416D4, https://asof.is/claim/clm_E888336416D4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000030/0001804220-20-000030-index.htm.","url":"https://asof.is/claim/clm_E888336416D4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"2,294,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E888336416D4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 842,100,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_EB2A23BDB86D, https://asof.is/claim/clm_EB2A23BDB86D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000030/0001804220-20-000030-index.htm.","url":"https://asof.is/claim/clm_EB2A23BDB86D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"842,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EB2A23BDB86D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,053,100,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_EF16715A0E38, https://asof.is/claim/clm_EF16715A0E38, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000030/0001804220-20-000030-index.htm.","url":"https://asof.is/claim/clm_EF16715A0E38","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,053,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EF16715A0E38","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 3,513,200,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_0AB6F3A48383, https://asof.is/claim/clm_0AB6F3A48383, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000008/0001804220-21-000008-index.htm.","url":"https://asof.is/claim/clm_0AB6F3A48383","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"3,513,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0AB6F3A48383","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2020, filed 2021-02-08"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 11,025,300,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_155A4F299072, https://asof.is/claim/clm_155A4F299072, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000008/0001804220-21-000008-index.htm.","url":"https://asof.is/claim/clm_155A4F299072","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"11,025,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_155A4F299072","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2020, filed 2021-02-08"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 2,735,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_55C14CEED321, https://asof.is/claim/clm_55C14CEED321, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000008/0001804220-21-000008-index.htm.","url":"https://asof.is/claim/clm_55C14CEED321","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,735,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_55C14CEED321","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2020, filed 2021-02-08"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 17,163,300,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_6964829D3216, https://asof.is/claim/clm_6964829D3216, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000008/0001804220-21-000008-index.htm.","url":"https://asof.is/claim/clm_6964829D3216","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"17,163,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6964829D3216","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2020, filed 2021-02-08"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 8,497,100,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_9C8093C9515A, https://asof.is/claim/clm_9C8093C9515A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000008/0001804220-21-000008-index.htm.","url":"https://asof.is/claim/clm_9C8093C9515A","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"8,497,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9C8093C9515A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2020, filed 2021-02-08"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 3,576,600,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_B1B09D53441E, https://asof.is/claim/clm_B1B09D53441E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000008/0001804220-21-000008-index.htm.","url":"https://asof.is/claim/clm_B1B09D53441E","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"3,576,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B1B09D53441E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2020, filed 2021-02-08"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,193,700,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_DC54DFD6D27B, https://asof.is/claim/clm_DC54DFD6D27B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000008/0001804220-21-000008-index.htm.","url":"https://asof.is/claim/clm_DC54DFD6D27B","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,193,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC54DFD6D27B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2020, filed 2021-02-08"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,437,900,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_2315D6C49C3A, https://asof.is/claim/clm_2315D6C49C3A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000017/0001804220-21-000017-index.htm.","url":"https://asof.is/claim/clm_2315D6C49C3A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,437,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2315D6C49C3A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2021, filed 2021-05-06"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 17,772,200,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_2CFC5ECC25A5, https://asof.is/claim/clm_2CFC5ECC25A5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000017/0001804220-21-000017-index.htm.","url":"https://asof.is/claim/clm_2CFC5ECC25A5","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"17,772,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2CFC5ECC25A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2021, filed 2021-05-06"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 742,900,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_4272E4D045DC, https://asof.is/claim/clm_4272E4D045DC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000017/0001804220-21-000017-index.htm.","url":"https://asof.is/claim/clm_4272E4D045DC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"742,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4272E4D045DC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2021, filed 2021-05-06"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 11,977,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_51B4B52D2498, https://asof.is/claim/clm_51B4B52D2498, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000017/0001804220-21-000017-index.htm.","url":"https://asof.is/claim/clm_51B4B52D2498","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"11,977,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_51B4B52D2498","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2021, filed 2021-05-06"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,112,700,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_6CF3EC7239A5, https://asof.is/claim/clm_6CF3EC7239A5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000017/0001804220-21-000017-index.htm.","url":"https://asof.is/claim/clm_6CF3EC7239A5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,112,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6CF3EC7239A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2021, filed 2021-05-06"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 2,528,700,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_9488B81B5C8C, https://asof.is/claim/clm_9488B81B5C8C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000017/0001804220-21-000017-index.htm.","url":"https://asof.is/claim/clm_9488B81B5C8C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"2,528,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9488B81B5C8C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2021, filed 2021-05-06"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,115,200,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_C9912D8698CC, https://asof.is/claim/clm_C9912D8698CC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000017/0001804220-21-000017-index.htm.","url":"https://asof.is/claim/clm_C9912D8698CC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,115,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C9912D8698CC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2021, filed 2021-05-06"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 21,485,900,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_17B10E4A6B92, https://asof.is/claim/clm_17B10E4A6B92, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000025/0001804220-21-000025-index.htm.","url":"https://asof.is/claim/clm_17B10E4A6B92","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"21,485,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_17B10E4A6B92","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2021, filed 2021-08-05"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 15,127,300,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_3AF93363CB9B, https://asof.is/claim/clm_3AF93363CB9B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000025/0001804220-21-000025-index.htm.","url":"https://asof.is/claim/clm_3AF93363CB9B","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"15,127,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3AF93363CB9B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2021, filed 2021-08-05"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 3,098,900,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_584F4235D169, https://asof.is/claim/clm_584F4235D169, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000025/0001804220-21-000025-index.htm.","url":"https://asof.is/claim/clm_584F4235D169","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"3,098,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_584F4235D169","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-05"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 714,200,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_983BBC03A998, https://asof.is/claim/clm_983BBC03A998, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000025/0001804220-21-000025-index.htm.","url":"https://asof.is/claim/clm_983BBC03A998","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"714,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_983BBC03A998","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2021, filed 2021-08-05"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,072,200,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_C7438CFA174A, https://asof.is/claim/clm_C7438CFA174A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000025/0001804220-21-000025-index.htm.","url":"https://asof.is/claim/clm_C7438CFA174A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,072,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C7438CFA174A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2021, filed 2021-08-05"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 5,138,500,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_CBD2A7149F84, https://asof.is/claim/clm_CBD2A7149F84, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000025/0001804220-21-000025-index.htm.","url":"https://asof.is/claim/clm_CBD2A7149F84","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,138,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CBD2A7149F84","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2021, filed 2021-08-05"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 3,347,200,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_F95FA506C1D9, https://asof.is/claim/clm_F95FA506C1D9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000025/0001804220-21-000025-index.htm.","url":"https://asof.is/claim/clm_F95FA506C1D9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,347,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F95FA506C1D9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-05"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,632,200,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_0F99CB02E0F4, https://asof.is/claim/clm_0F99CB02E0F4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000033/0001804220-21-000033-index.htm.","url":"https://asof.is/claim/clm_0F99CB02E0F4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,632,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0F99CB02E0F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-04"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,847,200,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_71265B6402D6, https://asof.is/claim/clm_71265B6402D6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000033/0001804220-21-000033-index.htm.","url":"https://asof.is/claim/clm_71265B6402D6","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,847,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_71265B6402D6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-04"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 23,671,500,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_75F778627304, https://asof.is/claim/clm_75F778627304, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000033/0001804220-21-000033-index.htm.","url":"https://asof.is/claim/clm_75F778627304","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"23,671,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_75F778627304","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2021, filed 2021-11-04"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 17,258,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_9723C6E3E8CC, https://asof.is/claim/clm_9723C6E3E8CC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000033/0001804220-21-000033-index.htm.","url":"https://asof.is/claim/clm_9723C6E3E8CC","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"17,258,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9723C6E3E8CC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2021, filed 2021-11-04"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 665,400,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_D602B5B0E5C5, https://asof.is/claim/clm_D602B5B0E5C5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000033/0001804220-21-000033-index.htm.","url":"https://asof.is/claim/clm_D602B5B0E5C5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"665,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D602B5B0E5C5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2021, filed 2021-11-04"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,432,400,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_F8115487CBB7, https://asof.is/claim/clm_F8115487CBB7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000033/0001804220-21-000033-index.htm.","url":"https://asof.is/claim/clm_F8115487CBB7","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,432,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F8115487CBB7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2021, filed 2021-11-04"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,452,800,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_FC7E3BF6DC06, https://asof.is/claim/clm_FC7E3BF6DC06, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422021000033/0001804220-21-000033-index.htm.","url":"https://asof.is/claim/clm_FC7E3BF6DC06","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,452,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FC7E3BF6DC06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2021, filed 2021-11-04"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 18,768,800,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_193A31C30AA8, https://asof.is/claim/clm_193A31C30AA8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000007/0001804220-22-000007-index.htm.","url":"https://asof.is/claim/clm_193A31C30AA8","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"18,768,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_193A31C30AA8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2021, filed 2022-02-07"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,885,600,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_36EE1EF9B7BE, https://asof.is/claim/clm_36EE1EF9B7BE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000007/0001804220-22-000007-index.htm.","url":"https://asof.is/claim/clm_36EE1EF9B7BE","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,885,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_36EE1EF9B7BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2021, filed 2022-02-07"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 2,908,100,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_49AC730473CC, https://asof.is/claim/clm_49AC730473CC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000007/0001804220-22-000007-index.htm.","url":"https://asof.is/claim/clm_49AC730473CC","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,908,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_49AC730473CC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2021, filed 2022-02-07"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 25,434,800,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_90E01C153E99, https://asof.is/claim/clm_90E01C153E99, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000007/0001804220-22-000007-index.htm.","url":"https://asof.is/claim/clm_90E01C153E99","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"25,434,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_90E01C153E99","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2021, filed 2022-02-07"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 16,071,700,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_99583435A585, https://asof.is/claim/clm_99583435A585, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000007/0001804220-22-000007-index.htm.","url":"https://asof.is/claim/clm_99583435A585","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"16,071,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_99583435A585","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2021, filed 2022-02-07"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 8,946,800,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_C2D9EB28F08E, https://asof.is/claim/clm_C2D9EB28F08E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000007/0001804220-22-000007-index.htm.","url":"https://asof.is/claim/clm_C2D9EB28F08E","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"8,946,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C2D9EB28F08E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2021, filed 2022-02-07"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 8,075,300,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_D26172E0F6F8, https://asof.is/claim/clm_D26172E0F6F8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000007/0001804220-22-000007-index.htm.","url":"https://asof.is/claim/clm_D26172E0F6F8","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"8,075,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D26172E0F6F8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2021, filed 2022-02-07"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 19,914,700,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_1515428319F6, https://asof.is/claim/clm_1515428319F6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm.","url":"https://asof.is/claim/clm_1515428319F6","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"19,914,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1515428319F6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2022, filed 2022-05-04"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,345,700,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_376D9CFEB579, https://asof.is/claim/clm_376D9CFEB579, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm.","url":"https://asof.is/claim/clm_376D9CFEB579","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,345,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_376D9CFEB579","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2022, filed 2022-05-04"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 973,500,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_41984D40F359, https://asof.is/claim/clm_41984D40F359, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm.","url":"https://asof.is/claim/clm_41984D40F359","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"973,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_41984D40F359","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-04"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 843,800,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_55A89BC77171, https://asof.is/claim/clm_55A89BC77171, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm.","url":"https://asof.is/claim/clm_55A89BC77171","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"843,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_55A89BC77171","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2022, filed 2022-05-04"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 26,348,700,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_723458921D36, https://asof.is/claim/clm_723458921D36, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm.","url":"https://asof.is/claim/clm_723458921D36","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"26,348,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_723458921D36","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2022, filed 2022-05-04"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,258,500,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_8A11620CC590, https://asof.is/claim/clm_8A11620CC590, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm.","url":"https://asof.is/claim/clm_8A11620CC590","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,258,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A11620CC590","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-04"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 2,965,100,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_DA35C89878EA, https://asof.is/claim/clm_DA35C89878EA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm.","url":"https://asof.is/claim/clm_DA35C89878EA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"2,965,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DA35C89878EA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2022, filed 2022-05-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 20,687,800,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_5C8D7A0356F3, https://asof.is/claim/clm_5C8D7A0356F3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000023/0001804220-22-000023-index.htm.","url":"https://asof.is/claim/clm_5C8D7A0356F3","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"20,687,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5C8D7A0356F3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2022, filed 2022-08-03"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,395,100,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_697E428F102E, https://asof.is/claim/clm_697E428F102E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000023/0001804220-22-000023-index.htm.","url":"https://asof.is/claim/clm_697E428F102E","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,395,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_697E428F102E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2022, filed 2022-08-03"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 2,857,200,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_704A9CC6C45D, https://asof.is/claim/clm_704A9CC6C45D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000023/0001804220-22-000023-index.htm.","url":"https://asof.is/claim/clm_704A9CC6C45D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"2,857,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_704A9CC6C45D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2022, filed 2022-08-03"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 27,205,800,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_AA7919F3BECF, https://asof.is/claim/clm_AA7919F3BECF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000023/0001804220-22-000023-index.htm.","url":"https://asof.is/claim/clm_AA7919F3BECF","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"27,205,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AA7919F3BECF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2022, filed 2022-08-03"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 852,100,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_B9D9CE7C44B8, https://asof.is/claim/clm_B9D9CE7C44B8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000023/0001804220-22-000023-index.htm.","url":"https://asof.is/claim/clm_B9D9CE7C44B8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"852,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B9D9CE7C44B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-03"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,109,900,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_C525B24D421A, https://asof.is/claim/clm_C525B24D421A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000023/0001804220-22-000023-index.htm.","url":"https://asof.is/claim/clm_C525B24D421A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,109,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C525B24D421A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-03"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 794,300,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_DC9A1606D340, https://asof.is/claim/clm_DC9A1606D340, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000023/0001804220-22-000023-index.htm.","url":"https://asof.is/claim/clm_DC9A1606D340","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"794,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC9A1606D340","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2022, filed 2022-08-03"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,491,300,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_018DAD07A3D9, https://asof.is/claim/clm_018DAD07A3D9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000031/0001804220-22-000031-index.htm.","url":"https://asof.is/claim/clm_018DAD07A3D9","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,491,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_018DAD07A3D9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2022, filed 2022-11-03"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,315,700,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_165D233486E7, https://asof.is/claim/clm_165D233486E7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000031/0001804220-22-000031-index.htm.","url":"https://asof.is/claim/clm_165D233486E7","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,315,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_165D233486E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-03"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 21,438,800,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_3798FEF555E2, https://asof.is/claim/clm_3798FEF555E2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000031/0001804220-22-000031-index.htm.","url":"https://asof.is/claim/clm_3798FEF555E2","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"21,438,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3798FEF555E2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2022, filed 2022-11-03"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 2,936,200,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_41EB8CF3FDDA, https://asof.is/claim/clm_41EB8CF3FDDA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000031/0001804220-22-000031-index.htm.","url":"https://asof.is/claim/clm_41EB8CF3FDDA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"2,936,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_41EB8CF3FDDA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2022, filed 2022-11-03"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 911,300,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_59B0EE58F0CA, https://asof.is/claim/clm_59B0EE58F0CA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000031/0001804220-22-000031-index.htm.","url":"https://asof.is/claim/clm_59B0EE58F0CA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"911,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_59B0EE58F0CA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2022, filed 2022-11-03"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,223,700,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_667CCF40E6E7, https://asof.is/claim/clm_667CCF40E6E7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000031/0001804220-22-000031-index.htm.","url":"https://asof.is/claim/clm_667CCF40E6E7","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,223,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_667CCF40E6E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-03"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 27,677,800,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_8BDAA49A5644, https://asof.is/claim/clm_8BDAA49A5644, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000031/0001804220-22-000031-index.htm.","url":"https://asof.is/claim/clm_8BDAA49A5644","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"27,677,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8BDAA49A5644","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2022, filed 2022-11-03"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 4,738,900,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_1DC3E40C4DC4, https://asof.is/claim/clm_1DC3E40C4DC4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm.","url":"https://asof.is/claim/clm_1DC3E40C4DC4","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"4,738,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1DC3E40C4DC4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2022, filed 2023-02-06"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 4,338,400,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_2FCCACC23EDE, https://asof.is/claim/clm_2FCCACC23EDE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm.","url":"https://asof.is/claim/clm_2FCCACC23EDE","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"4,338,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2FCCACC23EDE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2022, filed 2023-02-06"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,105,900,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_62434FDD6FF4, https://asof.is/claim/clm_62434FDD6FF4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm.","url":"https://asof.is/claim/clm_62434FDD6FF4","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,105,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_62434FDD6FF4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-06"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 12,172,900,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_6E857BE187DF, https://asof.is/claim/clm_6E857BE187DF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm.","url":"https://asof.is/claim/clm_6E857BE187DF","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"12,172,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6E857BE187DF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2022, filed 2023-02-06"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 3,592,500,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_80493D8A003C, https://asof.is/claim/clm_80493D8A003C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm.","url":"https://asof.is/claim/clm_80493D8A003C","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"3,592,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_80493D8A003C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2022, filed 2023-02-06"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 22,664,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_859C44BF3D2E, https://asof.is/claim/clm_859C44BF3D2E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm.","url":"https://asof.is/claim/clm_859C44BF3D2E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"22,664,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_859C44BF3D2E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2022, filed 2023-02-06"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 29,214,500,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_A6FC9F35DA9A, https://asof.is/claim/clm_A6FC9F35DA9A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm.","url":"https://asof.is/claim/clm_A6FC9F35DA9A","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"29,214,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A6FC9F35DA9A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2022, filed 2023-02-06"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 30,059,900,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_0963A3E9D139, https://asof.is/claim/clm_0963A3E9D139, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/0001804220-23-000016-index.htm.","url":"https://asof.is/claim/clm_0963A3E9D139","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"30,059,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0963A3E9D139","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,162,100,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_179FAEBC31F3, https://asof.is/claim/clm_179FAEBC31F3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/0001804220-23-000016-index.htm.","url":"https://asof.is/claim/clm_179FAEBC31F3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,162,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_179FAEBC31F3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,101,200,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_7DFE5AEE2C50, https://asof.is/claim/clm_7DFE5AEE2C50, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/0001804220-23-000016-index.htm.","url":"https://asof.is/claim/clm_7DFE5AEE2C50","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,101,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7DFE5AEE2C50","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,916,300,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_7E7BB784381A, https://asof.is/claim/clm_7E7BB784381A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/0001804220-23-000016-index.htm.","url":"https://asof.is/claim/clm_7E7BB784381A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,916,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7E7BB784381A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 817,800,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_802196BED548, https://asof.is/claim/clm_802196BED548, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/0001804220-23-000016-index.htm.","url":"https://asof.is/claim/clm_802196BED548","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"817,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_802196BED548","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 946,700,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_D8EB51091FB4, https://asof.is/claim/clm_D8EB51091FB4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/0001804220-23-000016-index.htm.","url":"https://asof.is/claim/clm_D8EB51091FB4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"946,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D8EB51091FB4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 23,495,200,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_E4AE0A080B44, https://asof.is/claim/clm_E4AE0A080B44, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/0001804220-23-000016-index.htm.","url":"https://asof.is/claim/clm_E4AE0A080B44","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"23,495,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E4AE0A080B44","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,158,100,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_03FC6245728F, https://asof.is/claim/clm_03FC6245728F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/0001804220-23-000023-index.htm.","url":"https://asof.is/claim/clm_03FC6245728F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,158,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_03FC6245728F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 968,400,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_0598850A1A59, https://asof.is/claim/clm_0598850A1A59, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/0001804220-23-000023-index.htm.","url":"https://asof.is/claim/clm_0598850A1A59","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"968,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0598850A1A59","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,016,500,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_0742E18258B7, https://asof.is/claim/clm_0742E18258B7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/0001804220-23-000023-index.htm.","url":"https://asof.is/claim/clm_0742E18258B7","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,016,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0742E18258B7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 30,657,500,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_4CC63E98652A, https://asof.is/claim/clm_4CC63E98652A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/0001804220-23-000023-index.htm.","url":"https://asof.is/claim/clm_4CC63E98652A","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"30,657,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4CC63E98652A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,085,300,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_7BB6A57A5F50, https://asof.is/claim/clm_7BB6A57A5F50, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/0001804220-23-000023-index.htm.","url":"https://asof.is/claim/clm_7BB6A57A5F50","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,085,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7BB6A57A5F50","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 24,017,900,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_C2064E6D19CF, https://asof.is/claim/clm_C2064E6D19CF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/0001804220-23-000023-index.htm.","url":"https://asof.is/claim/clm_C2064E6D19CF","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"24,017,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C2064E6D19CF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,937,200,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_F903F28AA80F, https://asof.is/claim/clm_F903F28AA80F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/0001804220-23-000023-index.htm.","url":"https://asof.is/claim/clm_F903F28AA80F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,937,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F903F28AA80F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,007,800,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_0089CAC97396, https://asof.is/claim/clm_0089CAC97396, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/0001804220-23-000031-index.htm.","url":"https://asof.is/claim/clm_0089CAC97396","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,007,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0089CAC97396","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 24,904,400,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_426EFFDCB275, https://asof.is/claim/clm_426EFFDCB275, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/0001804220-23-000031-index.htm.","url":"https://asof.is/claim/clm_426EFFDCB275","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"24,904,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_426EFFDCB275","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,075,300,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_5C3B864B89C2, https://asof.is/claim/clm_5C3B864B89C2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/0001804220-23-000031-index.htm.","url":"https://asof.is/claim/clm_5C3B864B89C2","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,075,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5C3B864B89C2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 32,163,300,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_924A6CAD98A4, https://asof.is/claim/clm_924A6CAD98A4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/0001804220-23-000031-index.htm.","url":"https://asof.is/claim/clm_924A6CAD98A4","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"32,163,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_924A6CAD98A4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,362,700,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_D14890ED012F, https://asof.is/claim/clm_D14890ED012F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/0001804220-23-000031-index.htm.","url":"https://asof.is/claim/clm_D14890ED012F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,362,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D14890ED012F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,111,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_D79F18FC7528, https://asof.is/claim/clm_D79F18FC7528, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/0001804220-23-000031-index.htm.","url":"https://asof.is/claim/clm_D79F18FC7528","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,111,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D79F18FC7528","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,152,300,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_FD93D07E05CD, https://asof.is/claim/clm_FD93D07E05CD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/0001804220-23-000031-index.htm.","url":"https://asof.is/claim/clm_FD93D07E05CD","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,152,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FD93D07E05CD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 13,117,200,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_0A05777F6B3A, https://asof.is/claim/clm_0A05777F6B3A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/0001804220-24-000009-index.htm.","url":"https://asof.is/claim/clm_0A05777F6B3A","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"13,117,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0A05777F6B3A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2023, filed 2024-02-05"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 3,953,600,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_11400CA0B8A6, https://asof.is/claim/clm_11400CA0B8A6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/0001804220-24-000009-index.htm.","url":"https://asof.is/claim/clm_11400CA0B8A6","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"3,953,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_11400CA0B8A6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2023, filed 2024-02-05"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 33,080,200,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_24DDC4DBA718, https://asof.is/claim/clm_24DDC4DBA718, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/0001804220-24-000009-index.htm.","url":"https://asof.is/claim/clm_24DDC4DBA718","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"33,080,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_24DDC4DBA718","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2023, filed 2024-02-05"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 4,439,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_5546754D63D6, https://asof.is/claim/clm_5546754D63D6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/0001804220-24-000009-index.htm.","url":"https://asof.is/claim/clm_5546754D63D6","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"4,439,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5546754D63D6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2023, filed 2024-02-05"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 4,047,100,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_5B0035249BB7, https://asof.is/claim/clm_5B0035249BB7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/0001804220-24-000009-index.htm.","url":"https://asof.is/claim/clm_5B0035249BB7","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"4,047,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5B0035249BB7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2023, filed 2024-02-05"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,730,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_65E6ADFD0D80, https://asof.is/claim/clm_65E6ADFD0D80, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/0001804220-24-000009-index.htm.","url":"https://asof.is/claim/clm_65E6ADFD0D80","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,730,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_65E6ADFD0D80","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2023, filed 2024-02-05"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 25,973,100,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_FF328F070B8B, https://asof.is/claim/clm_FF328F070B8B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/0001804220-24-000009-index.htm.","url":"https://asof.is/claim/clm_FF328F070B8B","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"25,973,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FF328F070B8B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2023, filed 2024-02-05"}},{"date":"2024-02-01","until":null,"published":"2026-04-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cfo: Christopher Fenimore\", as of 2024-02-01. Claim clm_0D057E1B2379, https://asof.is/claim/clm_0D057E1B2379, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm.","url":"https://asof.is/claim/clm_0D057E1B2379","accessed":"2026-11-09"},"kind":"people","predicate":"cfo","value":"Christopher Fenimore","status":"valid","assertable":true,"id":"clm_0D057E1B2379","evidence":{"by":"page-read","on":"2026-11-09","quote":"Effective February 2024, the board appointed Christopher Fenimore to succeed Robert E. Landry as the Company’s Chief Financial Officer upon Mr. Landry’s retirement.","url":"https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 751,400,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_5DA47B349189, https://asof.is/claim/clm_5DA47B349189, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000017/0001804220-24-000017-index.htm.","url":"https://asof.is/claim/clm_5DA47B349189","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"751,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5DA47B349189","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 26,991,100,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_792E7538AC26, https://asof.is/claim/clm_792E7538AC26, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000017/0001804220-24-000017-index.htm.","url":"https://asof.is/claim/clm_792E7538AC26","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"26,991,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_792E7538AC26","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,248,400,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_833AAF046462, https://asof.is/claim/clm_833AAF046462, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000017/0001804220-24-000017-index.htm.","url":"https://asof.is/claim/clm_833AAF046462","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,248,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_833AAF046462","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 34,369,600,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_89235EAA3408, https://asof.is/claim/clm_89235EAA3408, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000017/0001804220-24-000017-index.htm.","url":"https://asof.is/claim/clm_89235EAA3408","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"34,369,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_89235EAA3408","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,145,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_A39660FD9A27, https://asof.is/claim/clm_A39660FD9A27, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000017/0001804220-24-000017-index.htm.","url":"https://asof.is/claim/clm_A39660FD9A27","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,145,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A39660FD9A27","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,602,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_BB705899FBD2, https://asof.is/claim/clm_BB705899FBD2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000017/0001804220-24-000017-index.htm.","url":"https://asof.is/claim/clm_BB705899FBD2","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,602,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BB705899FBD2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 722,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_D6451915A936, https://asof.is/claim/clm_D6451915A936, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000017/0001804220-24-000017-index.htm.","url":"https://asof.is/claim/clm_D6451915A936","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"722,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D6451915A936","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,432,300,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_01E985023556, https://asof.is/claim/clm_01E985023556, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm.","url":"https://asof.is/claim/clm_01E985023556","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,432,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_01E985023556","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-01"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,547,100,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_3891C0E928C4, https://asof.is/claim/clm_3891C0E928C4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm.","url":"https://asof.is/claim/clm_3891C0E928C4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,547,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3891C0E928C4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2024, filed 2024-08-01"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 36,086,800,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_567F86365DD5, https://asof.is/claim/clm_567F86365DD5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm.","url":"https://asof.is/claim/clm_567F86365DD5","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"36,086,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_567F86365DD5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2024, filed 2024-08-01"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,200,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_6410B4B55A22, https://asof.is/claim/clm_6410B4B55A22, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm.","url":"https://asof.is/claim/clm_6410B4B55A22","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,200,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6410B4B55A22","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2024, filed 2024-08-01"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,069,600,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_9B13454F52AA, https://asof.is/claim/clm_9B13454F52AA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm.","url":"https://asof.is/claim/clm_9B13454F52AA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,069,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9B13454F52AA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-01"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,920,700,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_B12373EE7B0C, https://asof.is/claim/clm_B12373EE7B0C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm.","url":"https://asof.is/claim/clm_B12373EE7B0C","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,920,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B12373EE7B0C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2024, filed 2024-08-01"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 28,205,800,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_E2B4233513FC, https://asof.is/claim/clm_E2B4233513FC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm.","url":"https://asof.is/claim/clm_E2B4233513FC","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"28,205,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E2B4233513FC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2024, filed 2024-08-01"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 37,441,900,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_58CF60C9C3BB, https://asof.is/claim/clm_58CF60C9C3BB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm.","url":"https://asof.is/claim/clm_58CF60C9C3BB","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"37,441,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_58CF60C9C3BB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,011,800,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_616C3B8DE457, https://asof.is/claim/clm_616C3B8DE457, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm.","url":"https://asof.is/claim/clm_616C3B8DE457","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,011,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_616C3B8DE457","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,271,500,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_61BE04D629BB, https://asof.is/claim/clm_61BE04D629BB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm.","url":"https://asof.is/claim/clm_61BE04D629BB","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,271,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_61BE04D629BB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,720,700,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_A6AD04E866B3, https://asof.is/claim/clm_A6AD04E866B3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm.","url":"https://asof.is/claim/clm_A6AD04E866B3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,720,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A6AD04E866B3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,340,600,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_B2193D668623, https://asof.is/claim/clm_B2193D668623, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm.","url":"https://asof.is/claim/clm_B2193D668623","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,340,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B2193D668623","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,179,500,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_EB508637D538, https://asof.is/claim/clm_EB508637D538, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm.","url":"https://asof.is/claim/clm_EB508637D538","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,179,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EB508637D538","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 29,325,900,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_F515E2AB009D, https://asof.is/claim/clm_F515E2AB009D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm.","url":"https://asof.is/claim/clm_F515E2AB009D","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"29,325,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F515E2AB009D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 3,990,700,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_398CD3D76930, https://asof.is/claim/clm_398CD3D76930, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_398CD3D76930","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"3,990,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_398CD3D76930","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 29,353,600,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_3F5BAE27E768, https://asof.is/claim/clm_3F5BAE27E768, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_3F5BAE27E768","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"29,353,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3F5BAE27E768","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 37,759,400,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_428AF772B422, https://asof.is/claim/clm_428AF772B422, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_428AF772B422","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"37,759,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_428AF772B422","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 4,412,600,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_4E27594C511A, https://asof.is/claim/clm_4E27594C511A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_4E27594C511A","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"4,412,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4E27594C511A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 5,132,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_C301E7CAF361, https://asof.is/claim/clm_C301E7CAF361, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_C301E7CAF361","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"5,132,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C301E7CAF361","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 14,202,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_EE95AAD2339E, https://asof.is/claim/clm_EE95AAD2339E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_EE95AAD2339E","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"14,202,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EE95AAD2339E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,488,200,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_F0F5921A0058, https://asof.is/claim/clm_F0F5921A0058, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_F0F5921A0058","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,488,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F0F5921A0058","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2024, filed 2025-02-05"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,028,700,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_04C1A63A27E9, https://asof.is/claim/clm_04C1A63A27E9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/0001804220-25-000022-index.htm.","url":"https://asof.is/claim/clm_04C1A63A27E9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,028,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_04C1A63A27E9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2025, filed 2025-04-29"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 591,700,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_3F78C327F519, https://asof.is/claim/clm_3F78C327F519, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/0001804220-25-000022-index.htm.","url":"https://asof.is/claim/clm_3F78C327F519","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"591,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3F78C327F519","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2025, filed 2025-04-29"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,327,400,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_4BF4BD70527E, https://asof.is/claim/clm_4BF4BD70527E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/0001804220-25-000022-index.htm.","url":"https://asof.is/claim/clm_4BF4BD70527E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,327,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4BF4BD70527E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2025, filed 2025-04-29"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 808,700,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_65FFF2CBF333, https://asof.is/claim/clm_65FFF2CBF333, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/0001804220-25-000022-index.htm.","url":"https://asof.is/claim/clm_65FFF2CBF333","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"808,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_65FFF2CBF333","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2025, filed 2025-04-29"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,090,200,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_775D46B7A29F, https://asof.is/claim/clm_775D46B7A29F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/0001804220-25-000022-index.htm.","url":"https://asof.is/claim/clm_775D46B7A29F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,090,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_775D46B7A29F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2025, filed 2025-04-29"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 29,387,600,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_B1CBF863516B, https://asof.is/claim/clm_B1CBF863516B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/0001804220-25-000022-index.htm.","url":"https://asof.is/claim/clm_B1CBF863516B","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"29,387,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B1CBF863516B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2025, filed 2025-04-29"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 37,545,200,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_DADAA2FC572E, https://asof.is/claim/clm_DADAA2FC572E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/0001804220-25-000022-index.htm.","url":"https://asof.is/claim/clm_DADAA2FC572E","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"37,545,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DADAA2FC572E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2025, filed 2025-04-29"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 38,219,200,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_0BB82D220F7E, https://asof.is/claim/clm_0BB82D220F7E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/0000872589-25-000019-index.htm.","url":"https://asof.is/claim/clm_0BB82D220F7E","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"38,219,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0BB82D220F7E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2025, filed 2025-08-01"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,079,500,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_0CA4006DEF0C, https://asof.is/claim/clm_0CA4006DEF0C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/0000872589-25-000019-index.htm.","url":"https://asof.is/claim/clm_0CA4006DEF0C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,079,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0CA4006DEF0C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-01"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 1,995,800,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_436CC0AE1280, https://asof.is/claim/clm_436CC0AE1280, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/0000872589-25-000019-index.htm.","url":"https://asof.is/claim/clm_436CC0AE1280","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,995,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_436CC0AE1280","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2025, filed 2025-08-01"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,675,600,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_43E679905BB9, https://asof.is/claim/clm_43E679905BB9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/0000872589-25-000019-index.htm.","url":"https://asof.is/claim/clm_43E679905BB9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,675,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_43E679905BB9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2025, filed 2025-08-01"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 29,938,900,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_4D236E01F288, https://asof.is/claim/clm_4D236E01F288, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/0000872589-25-000019-index.htm.","url":"https://asof.is/claim/clm_4D236E01F288","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"29,938,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4D236E01F288","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2025, filed 2025-08-01"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,421,700,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_7D676D307920, https://asof.is/claim/clm_7D676D307920, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/0000872589-25-000019-index.htm.","url":"https://asof.is/claim/clm_7D676D307920","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,421,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7D676D307920","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2025, filed 2025-08-01"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,391,600,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_80007FEE76CE, https://asof.is/claim/clm_80007FEE76CE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/0000872589-25-000019-index.htm.","url":"https://asof.is/claim/clm_80007FEE76CE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,391,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_80007FEE76CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-01"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,026,800,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_0F41A2F44A01, https://asof.is/claim/clm_0F41A2F44A01, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_0F41A2F44A01","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,026,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0F41A2F44A01","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-28"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,754,300,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_471EC2DBAE0B, https://asof.is/claim/clm_471EC2DBAE0B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_471EC2DBAE0B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,754,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_471EC2DBAE0B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-10-28"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,506,400,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_5CC511D1F933, https://asof.is/claim/clm_5CC511D1F933, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_5CC511D1F933","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,506,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5CC511D1F933","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-28"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,460,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_75B9586D5FEE, https://asof.is/claim/clm_75B9586D5FEE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_75B9586D5FEE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,460,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_75B9586D5FEE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-28"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 40,169,400,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_A47C41C5A48C, https://asof.is/claim/clm_A47C41C5A48C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_A47C41C5A48C","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"40,169,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A47C41C5A48C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-28"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 30,957,800,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_CF9BA729AF1E, https://asof.is/claim/clm_CF9BA729AF1E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_CF9BA729AF1E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"30,957,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CF9BA729AF1E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-28"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,475,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_F00F9DA4362C, https://asof.is/claim/clm_F00F9DA4362C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_F00F9DA4362C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,475,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F00F9DA4362C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2025, filed 2025-10-28"}},{"date":"2025-12-31","until":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 5,850,200,000 United States dollar\", as of 2025-12-31. Claim clm_1819F20C7CC4, https://asof.is/claim/clm_1819F20C7CC4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_1819F20C7CC4","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"5,850,200,000 United States dollar","status":"valid","assertable":true,"id":"clm_1819F20C7CC4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 3,577,900,000 United States dollar\", as of 2025-12-31. Claim clm_1B456AFB0CC5, https://asof.is/claim/clm_1B456AFB0CC5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_1B456AFB0CC5","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"3,577,900,000 United States dollar","status":"valid","assertable":true,"id":"clm_1B456AFB0CC5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 31,256,900,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_68C522C0BDED, https://asof.is/claim/clm_68C522C0BDED, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_68C522C0BDED","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"31,256,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_68C522C0BDED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 4,504,900,000 United States dollar\", as of 2025-12-31. Claim clm_7514724ED5E9, https://asof.is/claim/clm_7514724ED5E9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_7514724ED5E9","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"4,504,900,000 United States dollar","status":"valid","assertable":true,"id":"clm_7514724ED5E9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,118,100,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_B18C1963BC40, https://asof.is/claim/clm_B18C1963BC40, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_B18C1963BC40","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,118,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B18C1963BC40","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 40,558,700,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_CFD74D844717, https://asof.is/claim/clm_CFD74D844717, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_CFD74D844717","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"40,558,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CFD74D844717","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 14,342,900,000 United States dollar\", as of 2025-12-31. Claim clm_E5421E95D3E6, https://asof.is/claim/clm_E5421E95D3E6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_E5421E95D3E6","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"14,342,900,000 United States dollar","status":"valid","assertable":true,"id":"clm_E5421E95D3E6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-04"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,962,600,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_518E1E5FF285, https://asof.is/claim/clm_518E1E5FF285, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/0000872589-26-000016-index.htm.","url":"https://asof.is/claim/clm_518E1E5FF285","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,962,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_518E1E5FF285","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 727,200,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_55728063B1D6, https://asof.is/claim/clm_55728063B1D6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/0000872589-26-000016-index.htm.","url":"https://asof.is/claim/clm_55728063B1D6","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"727,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_55728063B1D6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 642,900,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_6BF4C3658A74, https://asof.is/claim/clm_6BF4C3658A74, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/0000872589-26-000016-index.htm.","url":"https://asof.is/claim/clm_6BF4C3658A74","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"642,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6BF4C3658A74","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 40,868,800,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_81C2322B5ECE, https://asof.is/claim/clm_81C2322B5ECE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/0000872589-26-000016-index.htm.","url":"https://asof.is/claim/clm_81C2322B5ECE","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"40,868,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_81C2322B5ECE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,605,400,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_89291214D4AA, https://asof.is/claim/clm_89291214D4AA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/0000872589-26-000016-index.htm.","url":"https://asof.is/claim/clm_89291214D4AA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"3,605,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_89291214D4AA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 31,423,600,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_98A5851FED3C, https://asof.is/claim/clm_98A5851FED3C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/0000872589-26-000016-index.htm.","url":"https://asof.is/claim/clm_98A5851FED3C","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"31,423,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_98A5851FED3C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,543,500,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_D76E4D0088C5, https://asof.is/claim/clm_D76E4D0088C5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/0000872589-26-000016-index.htm.","url":"https://asof.is/claim/clm_D76E4D0088C5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,543,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D76E4D0088C5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 41,730,600,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_0A911086D51B, https://asof.is/claim/clm_0A911086D51B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/0000872589-26-000025-index.htm.","url":"https://asof.is/claim/clm_0A911086D51B","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"41,730,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0A911086D51B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2026, filed 2026-07-30"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 4,290,700,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_11098E7F99BC, https://asof.is/claim/clm_11098E7F99BC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/0000872589-26-000025-index.htm.","url":"https://asof.is/claim/clm_11098E7F99BC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,290,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_11098E7F99BC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2026, filed 2026-07-30"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,631,600,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_223E08E3A074, https://asof.is/claim/clm_223E08E3A074, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/0000872589-26-000025-index.htm.","url":"https://asof.is/claim/clm_223E08E3A074","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,631,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_223E08E3A074","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2026, filed 2026-07-30"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,293,500,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_2721EF4559B5, https://asof.is/claim/clm_2721EF4559B5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/0000872589-26-000025-index.htm.","url":"https://asof.is/claim/clm_2721EF4559B5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,293,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2721EF4559B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2026, filed 2026-07-30"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,296,900,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_6178480D55DF, https://asof.is/claim/clm_6178480D55DF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/0000872589-26-000025-index.htm.","url":"https://asof.is/claim/clm_6178480D55DF","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,296,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6178480D55DF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2026, filed 2026-07-30"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,455,800,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_6D7C70396974, https://asof.is/claim/clm_6D7C70396974, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/0000872589-26-000025-index.htm.","url":"https://asof.is/claim/clm_6D7C70396974","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,455,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6D7C70396974","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2026, filed 2026-07-30"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 31,711,400,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_B9E0E558C863, https://asof.is/claim/clm_B9E0E558C863, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/0000872589-26-000025-index.htm.","url":"https://asof.is/claim/clm_B9E0E558C863","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"31,711,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B9E0E558C863","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2026, filed 2026-07-30"}},{"date":"2026-09-30","until":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 5,115,800,000 United States dollar\", as of 2026-09-30. Claim clm_15BDC7B1496E, https://asof.is/claim/clm_15BDC7B1496E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_15BDC7B1496E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,115,800,000 United States dollar","status":"valid","assertable":true,"id":"clm_15BDC7B1496E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-10-30"}},{"date":"2026-09-30","until":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 33,498,500,000 United States dollar\", as of 2026-09-30. Claim clm_24A29A7153C0, https://asof.is/claim/clm_24A29A7153C0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_24A29A7153C0","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"33,498,500,000 United States dollar","status":"valid","assertable":true,"id":"clm_24A29A7153C0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-10-30"}},{"date":"2026-09-30","until":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 2,048,200,000 United States dollar\", as of 2026-09-30. Claim clm_4585DB96888D, https://asof.is/claim/clm_4585DB96888D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_4585DB96888D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,048,200,000 United States dollar","status":"valid","assertable":true,"id":"clm_4585DB96888D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"date":"2026-09-30","until":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,794,700,000 United States dollar\", as of 2026-09-30. Claim clm_4D8C13296D0A, https://asof.is/claim/clm_4D8C13296D0A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_4D8C13296D0A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,794,700,000 United States dollar","status":"valid","assertable":true,"id":"clm_4D8C13296D0A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2026, filed 2026-10-30"}},{"date":"2026-09-30","until":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,659,100,000 United States dollar\", as of 2026-09-30. Claim clm_5EBA4C72A92F, https://asof.is/claim/clm_5EBA4C72A92F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_5EBA4C72A92F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,659,100,000 United States dollar","status":"valid","assertable":true,"id":"clm_5EBA4C72A92F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-10-30"}},{"date":"2026-09-30","until":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,948,700,000 United States dollar\", as of 2026-09-30. Claim clm_DEF587D6916A, https://asof.is/claim/clm_DEF587D6916A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_DEF587D6916A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,948,700,000 United States dollar","status":"valid","assertable":true,"id":"clm_DEF587D6916A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"date":"2026-09-30","until":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 44,405,200,000 United States dollar\", as of 2026-09-30. Claim clm_F46BE3EF6472, https://asof.is/claim/clm_F46BE3EF6472, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_F46BE3EF6472","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"44,405,200,000 United States dollar","status":"valid","assertable":true,"id":"clm_F46BE3EF6472","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-10-30"}}],"complete":true,"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing","page-read":"its source page states the value and the date"}}}